Formalization of molecular interaction maps in systems biology; Application to simulations of the relationship between DNA damage response and circadian rhythms by Luna, Augustin
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2013
Formalization of molecular
interaction maps in systems
biology; Application to simulations
of the relationship between DNA
damage response and circadian
rhythms
https://hdl.handle.net/2144/14143
Boston University
BOSTON UNIVERSITY 
GRADUATE SCHOOL OF ARTS AND SCIENCES 
AND 
COLLEGE OF ENGINEERING 
 
Dissertation 
 
FORMALIZATION OF MOLECULAR INTERACTION MAPS IN SYSTEMS 
BIOLOGY; APPLICATION TO SIMULATIONS OF THE RELATIONSHIP 
BETWEEN DNA DAMAGE RESPONSE AND CIRCADIAN RHYTHMS 
 
by 
 
AUGUSTIN LUNA 
B.S., Georgia Institute of Technology, 2005 
 
 
 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
2013  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by 
AUGUSTIN LUNA 
2013  
Approved by 
 
 
 
 
 
 
First Reader  ________________________________________________ 
Mirit I. Aladjem, Ph.D. 
Senior Investigator. Laboratory of Molecular Pharmacology, 
Center for Cancer Research, NCI, NIH 
 
 
 
 
 
Second Reader  ________________________________________________ 
Daniel Segrè, Ph.D. 
Professor of Bioinformatics 
Boston University 
 
 
 
 
iv 
Acknowledgements 
There are a lot of people I want to thank starting with my parents Pedro Luna and 
Maria Portillo who supported me academically when they did not have similar 
opportunities. I would like to thank Don Lohmeier, Teddie Lohmeier, Luis Romo, 
Lynne Romo and their families who provided me with many early opportunities 
and have given me encouragement. There are several scientific mentors that I 
would like to thank: Allen Tannebaum, Eli Hershkovitz, Andreas Bommarius, 
Karen Polizzi, Javier Chaparro-Riggers, Daniel Weinberger, Kristen Nicodemus, 
Daniel Segrè, and Ulla Hansen who gave me the opportunity conduct scientific 
work with them, as well as others who have guided me: Sally Gerrish, Sharon 
Milgram, and David Landsman. I would like to thank the Graduate Partnerships 
Program at the National Institutes of Health (NIH) and the close friends that I 
have made during my time at the NIH. More specifically, I would like to thank 
students of the Boston University partnership program: Gabriel Eichler, Loren 
Hansen, Brian Abraham, the late Wesley Beckstead and those of the Boston 
University program John Brothers, Josh Campbell, and Alexandra Dumitriu, who 
have helped me over the years. I would also like to thank the large number of 
colleagues I have had the chance to work with over the years in various labs, 
especially Melvenia Martin and Margot Sunshine, and their administrative staffs. 
Next, I would like to thank members of the SBML, BioPAX, and SBGN 
communities from whom I have learned a lot, including: Tobias Czauderna, Emek 
Demir, Itir Karac, Allan Kuchinsky, Martina Kutmon, Nicolas Le Novère, Huaiyu 
v 
Mi, Stuart Moodie, Alexander Pico, Falk Schreiber, Anatoly Sorokin, and Martijn 
van Iersel. None of this would be possible without the funding sources that have 
made this work possible, including: the Google Summer of Code program, Ford 
Foundation, and Intramural Research Program at the National Cancer Institute. 
Lastly, yet most importantly, I would like to thank Sohyoung Kim, Geoffrey 
McFadden, Kurt Kohn, and Mirit Aladjem who have been the bedrock of my 
support for this work. 
 
 
 
 
 
 
 
 
 
  
vi 
FORMALIZATION OF MOLECULAR INTERACTION MAPS IN SYSTEMS 
BIOLOGY; APPLICATION TO SIMULATIONS OF THE RELATIONSHIP 
BETWEEN DNA DAMAGE RESPONSE AND CIRCADIAN RHYTHMS 
 (Order No.                        ) 
AUGUSTIN LUNA 
Boston University Graduate School of Arts and Sciences  
and 
College of Engineering, 2013 
Major Professor:  Mirit I. Aladjem, Senior Investigator. Laboratory of Molecular 
Pharmacology, Center for Cancer Research, NCI, NIH 
 
ABSTRACT 
Quantitative exploration of biological pathway networks must begin with a 
qualitative understanding of them. Often researchers aggregate and disseminate 
experimental data using regulatory diagrams with ad hoc notations leading to 
ambiguous interpretations of presented results. This thesis has two main aims. 
First, it develops software to allow researchers to aggregate pathway data 
diagrammatically using the Molecular Interaction Map (MIM) notation in order to 
gain a better qualitative understanding of biological systems. Secondly, it 
develops a quantitative biological model to study the effect of DNA damage on 
circadian rhythms. The second aim benefits from the first by making use of visual 
representations to identify potential system boundaries for the quantitative model.  
 
vii 
I focus first on software for the MIM notation – a notation to concisely visualize 
bioregulatory complexity and to reduce ambiguity for readers. The thesis 
provides a formalized MIM specification for software implementation along with a 
base layer of software components for the inclusion of the MIM notation in other 
software packages. It also provides an implementation of the specification as a 
user-friendly tool, PathVisio-MIM, for creating and editing MIM diagrams along 
with software to validate and overlay external data onto the diagrams.  
 
I focus secondly on the application of the MIM software to the quantitative 
exploration of the poorly understood role of SIRT1 and PARP1, two NAD+-
dependent enzymes, in the regulation of circadian rhythms during DNA damage 
response. SIRT1 and PARP1 participate in the regulation of several key DNA 
damage-repair proteins and are the subjects of study as potential cancer 
therapeutic targets. In this part of the thesis, I present an ordinary differential 
equation (ODE) model that simulates the core circadian clock and the 
involvement of SIRT1 in both the positive and negative arms of circadian 
regulation. I then use this model is then used to predict a potential role for the 
competition for NAD+ supplies by SIRT1 and PARP1 leading to the observed 
behavior of primarily phase advancement of circadian oscillations during DNA 
damage response. The model further predicts a potential mechanism by which 
multiple forms of post-transcriptional modification may cooperate to produce a 
primarily phase advancement.  
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1 INTRODUCTION 
1.1 Dissertation Motivation and Overview 
The landscape of biomedical research is undergoing a shift from an era focused 
on the discovery of cellular constituents to one focused on the determination of 
interactions between molecular species (Lazebnik 2002). This shift is 
characterized through the development of formal representations of biological 
knowledge and predictive quantitative models of biological processes. These 
quantitative models contrast with models that use verbal descriptions currently 
found throughout biomedical research publications. Better known as “systems 
biology”, this area of research has its roots in quantitative models, such as the 
Hodgkin and Huxley model, which explored the functionality of neurons (Hodgkin 
and Huxley 1952).  
 
The integration of the findings of individual research groups, in terms of 
molecular interactions, ultimately leads us to a network view of biology and 
facilitates large-scale efforts to reconstruct genetic, protein, and metabolic 
networks in humans and model organisms (Schellenberger, Park et al. 2010; 
Chatr-Aryamontri, Breitkreutz et al. 2013). Such projects allow us to gain insight 
into network-level, emergent properties of these biological networks with 
implication to human health through understanding the interconnectedness of 
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human diseases and pharmacological responses (Goh, Cusick et al. 2007; 
Hopkins 2008). The network view of biology also allows researchers to examine 
generalized properties, such as feedback control and robustness, inherent to the 
function of all biological networks (Kim, Shay et al. 2009; Liu, Slotine et al. 2011).  
 
For all the potential benefits of a network-centric approach to biology, there are 
hurdles to the integration of experimental observations across individual 
experiments from various laboratories and research areas. Overcoming this 
problem of data integration requires formalized representations as the common 
languages in the integration process. The challenge of formalized 
representations is to generate representations that are simple for both users and 
developers and are flexible enough for dealing with use cases from a wide range 
of research areas. There are many efforts to develop formal representations in 
biology (Goddard, Hucka et al. 2001; Lloyd, Halstead et al. 2004; Christie, 
Nielsen et al. 2009; Waltemath, Adams et al. 2011). Two well-known projects are 
the Systems Biology Markup Language (SBML) and the Biological Pathways 
Exchange (BioPAX) format projects that cater to communities focused on the 
mathematic modeling of biological systems and knowledge representation of 
biological pathways, respectively (Hucka, Finney et al. 2003; Demir, Cary et al. 
2010).  
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One key aspect of the workflow of most biomedical researchers, but which is not 
the direct focus of either of SBML or BioPAX projects, is in the graphical 
representation of biological knowledge as a medium for sharing knowledge. 
Graphical illustrations can group and summarize large amounts of data and 
reduce the amount of search done by readers (Larkin and Simon 1987). History 
is filled with countless examples of the relationship of illustration and science in 
helping us understand natural phenomena from Leonardo Da Vinci, who helped 
pioneer the use of anatomical illustration, to Irving Geis, who illustrated 
myoglobin (one of the first proteins to have its structure characterized); scientific 
illustration can help not only represent current knowledge, but can also help drive 
discovery forward (Goodsell and Johnson 2007; Gelipter 2008). The usage of 
graphical representations in biochemistry can be traced as least as far back as 
the first half of the 20th century and their importance has continued with the 
advent of modern computational databases like KEGG, which has graphically 
depicted metabolic networks since its inception (Goto, Bono et al. 1997; Le 
Novère, Hucka et al. 2009).  
 
In 1999, Kurt Kohn developed the Molecular Interaction Map (MIM) notation as a 
potential standardized language for the graphical representation of biological 
signaling pathways (Kohn 1999). Core to the features of the notation has been its 
use of a small set of graphical elements and its focus on the reduction of visual 
complexity. This notation serves as a method for researchers to gain a better 
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understanding of signaling networks across multiple publications through the 
visual reconstruction of these biological networks. While highly cited, the notation 
in the past has suffered from a lack of software for simplifying its use and 
facilitating the storage of MIM diagrams in a machine-readable representation. 
Additionally, the notation has lacked a thorough specification that could be used 
for the mapping of the notation to other related efforts more focused on verbose 
textual representations of biological data, such as SBML and BioPAX. Therefore, 
I sought to improve the software support and readability for the graphical 
representation of biological signaling networks using the MIM notation and to 
provide both qualitative and quantitative use cases for the application of MIM 
notation.  
 
1.2 Dissertation aims 
Aim 1. Create a software implementation specification for the Molecular 
Interaction Map notation and suite of software tools for users of the 
notation.  
 
Diagrams can serve as methods for disseminating biological information in a 
concise manner. The Molecular Interaction Map (MIM) notation offers a set of 
glyphs and rules on their usage for depiction of cellular signaling network 
diagrams. A limitation in adoption of the notation is the lack of software for 
creating and editing diagrams using the notation prompting the need for the 
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creation of a MIM specific editor. As a first step towards the creation of the editor, 
a specification was created to outline the properties of the MIM notation. During 
the creation of the specification, implementation issues that hampered the 
translation of MIM to software were addressed; the scope of the notation was 
also extended to increase compatibility with existing bioinformatics standards and 
software (Chapter 2).  
 
This resulting specification then served as a guide for the creation of a machine-
readable format for MIM diagrams, an application programming interface (API), 
and a validation framework for MIM diagrams; together these tools act as a base 
layer of software support for developers (Chapter 2). This base layer of support 
was then used to develop an end-user layer of software support with the 
development of PathVisio-MIM (a MIM editor), PathVisio-Validator (a generic 
validation interface), and PathVisio-Faceted Search (a tool for exploring 
regulatory networks in the context of specific datasets) (Chapter 3).  
 
Aim 2. Using software developed in Aim 1, an extensive literature review of 
the interplay between SIRT1 and PARP1 is conducted. The interactions of 
the related network are represented as a MIM diagram.    
 
Maintenance of genomic integrity in response to damage is of vital importance to 
cellular function and survival. Response to DNA damage is a complicated 
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process that is not completely understood, and it involves many regulatory 
mechanisms involving many dozens, if not hundreds, of proteins. Two proteins 
SIRT1 and PARP1 were selected as the focus for a literature review based on 
their relationship to several key biological processes (e.g. metabolism, DNA 
damage response, circadian rhythms) and their potential as therapeutic targets 
for several diseases, including cancer.  
 
An intricate network regulates the activities of SIRT1 and PARP1 proteins and 
continues to be uncovered. Both SIRT1 and PARP1 share a common co-factor 
(NAD+) and several common substrates in the regulation of DNA damage 
response. Although the two proteins share a co-factor, the complexity of the 
surrounding regulatory network provides a challenging network for representation 
with the MIM notation as the basis for a quantitative model. This complex 
network of interactions visualized using a Molecular Interaction Map is used to 
explore the interplay between these two proteins (Chapter 4). Further discussed 
is how NAD+ competition and post-transcriptional/translational feedback 
mechanisms create a regulatory network sensitive to environmental cues, such 
as genotoxic stress and metabolic states. The discussion also examines the role 
of those interactions in DNA repair and ultimately, cell fate decisions.  
 
Aim 3. Develop an ordinary differential equation model of the dynamics of 
circadian rhythms in response to DNA damage with respect to functions of 
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SIRT1 and PARP1; the model is a subset of the interactions described in 
Aim 2. 
 
The circadian clock is a set of regulatory steps that oscillate with a period of 
approximately 24 hours influencing many biological processes. These oscillations 
are robust to external stresses, yet can be influenced by these stresses. In the 
case of genotoxic stress (i.e. DNA damage), the circadian clock responds 
through phase shifting with primarily phase advancements. The effect of DNA 
damage on circadian clock and the mechanism through which this effect 
operates remains to be thoroughly investigated. Built here was an in silico model 
to examine the phase shifting that occurs during DNA damage response by 
investigating a possible mechanism building on evidence linking circadian 
rhythms to metabolism. The proposed mechanism involves two DNA damage 
response proteins, SIRT1 and PARP1, which are each consumers of 
nicotinamide adenine dinucleotide (NAD), a metabolite involved in oxidation-
reduction reactions and in ATP synthesis. This model built on findings that show 
that SIRT1 (a protein deacetylase) is involved in both the positive (i.e. 
transcriptional activation) and negative (i.e. transcriptional repression) arms of 
the circadian regulation and that PARP1 is a major consumer of NAD+ during 
DNA damage response. Results from the simulated system indicated that 
increased PARP1 activity may be able to trigger the observed phase 
advancements by downregulating SIRT1 activity through its competition for 
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NAD+ supplies. We showed how this competition may affect circadian rhythms 
through acetylation events in conjunction with phosphorylation events that have 
also been predicted to be involved in the phase shifting behavior. These findings 
suggest a possible mechanism through which multiple perturbations each 
dominant during different points of the circadian cycle may account for the 
primarily phase advancement response seen during DNA damage perturbations 
of the circadian clock (Chapter 4). 
9 
 
 
2 A FORMAL MIM SPECIFICATION AND TOOLS FOR THE 
COMMON EXCHANGE OF MIM DIAGRAMS: AN XML-BASED 
FORMAT, AN API, AND A VALIDATION METHOD 
(Note: Chapter taken from:  
Luna A, Karac EI, Sunshine M, Chang L, Nussinov R, Aladjem MI, Kohn KW. A 
Formal MIM Specification and Tools for the Common Exchange of MIM 
Diagrams: an XML-Based Format, an API, and a Validation Method. BMC 
Bioinformatics 2011, 12:167.; Luna A contributions: created and tested the MIM 
API, MIMML schema, and MIM Schematron ruleset, wrote project documentation 
and example MIMML datasets, edited the specification, and wrote the 
manuscript) 
 
2.1 Introduction 
2.1.1 Molecular Interaction Maps  
Diagrams have long been used to organize knowledge, and there has been an 
ever-growing use of such diagrams in biological sciences in the last half century. 
As their use increases so does the need for common methods to communicate 
biological knowledge accurately from author to reader in a manner similar to 
other disciplines that use technical drawings. Advances in molecular biology 
experimental techniques have resulted in an abundance of high-throughput data, 
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placing additional emphasis on the need for the organization and visualization of 
biological data. Since its inception in 1999, the Molecular Interaction Map (MIM) 
notation has helped address this need for standardized representation of 
biochemical and cellular processes through a notation that shares visual 
characteristics with electrical circuit diagrams (Kohn 1999). The notation has 
been featured in a variety of publications as the mechanism used to organize 
biological information and the basis for mathematical simulations (Reinhold, 
Kouros-Mehr et al. 2003; Kohn, Riss et al. 2004; Pommier, Sordet et al. 2004; 
Kohn and Pommier 2005; Pommier, Sordet et al. 2005; Pommier, Weinstein et 
al. 2006; Bortolussi, Fonda et al. 2007; Kohn, Aladjem et al. 2008; Tozluoğlu, 
Karaca et al. 2008; Barbuti, Lepri et al. 2010; Castagnino, Tortolina et al. 2010; 
Hayes, McMahon et al. 2010; Kim, Aladjem et al. 2010). The MIM notation has 
also garnered wide attention in the systems biology community. It has been 
advocated as a notation for graphical display of purely textual datasets such as 
those based on the BioPAX ontology (BioPAX Workgroup 2005). The notation 
has also helped spur the creation of the Systems Biology Graphical Notation 
(SBGN) consortium, which has as a basis for its SBGN Entity-Relationship 
(SBGN ER) language, the MIM notation (Le Novère, Hucka et al. 2009; Le 
Novère, Moodie et al. 2010). There is the potential that at some future point in 
time these two graphical notations will converge entirely.  
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As the amount of data in MIM diagrams increases, the availability of that data 
becomes a priority because the diagrams can serve as sources of data to be 
mined. The information content of MIM diagrams is not limited to graphical 
representations. The majority of published MIM diagrams have a series of 
accompanying annotations. These annotations are ancillary information, such as 
comments, external links, and citations, that are denoted as labels on interaction 
lines (Kohn 1999). Annotations provide readers with additional insight into the 
systems they represent, which may not be captured by MIM glyphs (e.g. 
information regarding time, location, and sequence of events). These annotations 
have recently been mined in the work by McIntosh and Curran who built a MIM 
corpus that maps MIM annotations to passages from the original research 
articles (McIntosh and Curran 2009).   
 
The present work outlines an implementation of the MIM notation and provides a 
new specification and a series of software tools based on this specification. The 
new specification addresses previous ambiguities in the notation, provides 
definitions as a foundation for translation and a set of syntax rules for the 
validation of MIM diagrams; the specification is provided as Appendix A. This 
specification forms the basis of an XML-based format that includes elements to 
capture both the graphical and non-graphical elements of MIM diagrams. The 
next topic presented is a mechanism for validating MIM datasets according to the 
syntax rules found in the specification. Lastly, an application programming 
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interface (API) is provided as a support mechanism for developers to interact 
with specific features of the MIM format.  
 
2.2 Results 
2.2.1 Description of the Formal MIM Specification 
The MIM notation has been described previously in several publications (Kohn 
1999; Aladjem, Pasa et al. 2004; Kohn and Aladjem 2006; Kohn, Aladjem et al. 
2006). The formal implementation presented below is based on the most widely 
used features in the MIM notation as presented in 2006 (Kohn, Aladjem et al. 
2006), and retains the goal of the MIM notation to present unambiguous and 
accurate diagrams of biological systems, while simplifying the visualization of 
these diagrams. The complete MIM specification is provided as Appendix A and 
online on our project homepage (http://discover.nci.nih.gov/mim). 
 
2.2.2 MIM Notation Elements 
MIM diagrams represent bioregulatory networks involving graphical elements 
broadly divided into two categories: entity and interaction glyphs. Entities may 
represent objects in nature with physical structures, such as biological molecules 
(e.g. protein, DNA, RNA, etc), or non-physical objects, such as phenotypes, 
behaviors, perturbations, cell cycle states, etc. Interactions are relationships 
between an entity and other entities or interactions. Interactions between two 
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entities are represented in the form of binding interactions (e.g. the binding of 
calcium to calmodulin) or the transformation of one entity into another (e.g. the 
ADP and phosphate to ATP). An interaction between an entity and another 
interaction can be used to describe the influence the entity exerts on the 
interactions, such as the inhibition of binding between two proteins by a third. 
The basic graphical elements that represent MIM elements are referred to as 
glyphs and are shown in Figure 1; full details on their usage are provided in 
Appendix A.  
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Figure 1: Basic glyphs used in this implementation of the MIM notation. The MIM 
notation consists essentially of glyphs representing entities and interactions; shown are 
the independent glyphs. A description of the usage for all the glyphs in the MIM notation 
is provided in Appendix A. 
 
Entity glyphs are differentiated by their shapes, and the various types of 
interactions are represented by lines with different arrowheads or other line end-
marks. For some glyphs, the semantics of the glyph are determined by the 
context in which the glyph is used; examples of these cases include the 
production without loss and stimulation glyphs, the simple physical entity and 
entity feature glyphs, and restricted copy entity glyphs shown in Figure 1, while 
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Simple physical
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LABEL
LABEL
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LABEL:POSITION Modifier
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Reaction Glyphs
Non-covalent reversible binding 
Covalent modification
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explicit and implicit complex formation are shown in Figure 2. As has been the 
case with previous MIM specifications, the color of a glyph does not affect its 
semantics. The accompanying MIM specification describes the full set of MIM 
glyphs shown in Figure 1 and Figure 2 along with their appropriate use.  
 
 
Figure 2: More advanced use cases of MIM glyphs. Examples of cases involving 
multiple MIM glyphs to represent a concept. 
 
A
Dimer formation 
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2.2.3 Entity Glyphs 
The MIM notation supports various types of entities, each represented by a 
different glyph. The most common entity glyph is a labeled rounded-rectangle 
that represents a simple physical entity (SPEs) where “simple” denotes that the 
entity is not in a complex with other entities; this glyph is used to represent 
molecules such as proteins, DNA, RNA, etc. The labels of SPEs are the main 
identifiers used by readers in understanding MIM diagrams, and we therefore 
recommend that standardized nomenclatures, such as HGNC names should be 
used.  
 
An SPE can also be represented in a manner that defines specific regions of 
molecules, such as protein domains, motifs, and sites. This representation 
provides a more-detailed description of an SPE through the use of entity 
features. Entity features can be used to indicate specific regions of an SPE that 
carry out a particular function, as illustrated in Figure 2.  
 
SPEs are typically represented once in a given diagram, which allows for the 
traceability of all the interactions of a given entity to a single location on a 
diagram. An exception to this recommendation is modifiers that are represented 
as labels without borders and are generally used to represent small molecules 
(e.g. phosphate, methyl, ubiquitin molecules). Such small molecules tend to exist 
17 
 
 
frequently in pathway interactions, and it would be prohibitive to route all the 
connections of a small molecule to a single glyph.  
 
SPEs can exist in complexes with other entities. There are two types of 
complexes in MIM: explicit and implicit complexes as shown in Figure 2. Explicit 
complexes are diagrammed as small filled circles on binding interaction lines, 
and are termed “explicit” because the binding partners that give rise to them are 
shown. Implicit complexes, however, are diagrammed as enclosures of SPEs 
and indicate an implied relationship between the SPEs without showing their 
direct interactions. Figure 3 shows a complex of SPEs A, B, and C as an explicit 
complex. The interaction between A and B forms the complex A:B, which is then 
bound to C. As represented as an explicit complex, A and B cannot be unbound 
if C is bound to the A:B complex; this represents a common mechanism whereby 
C stabilizes the A:B interaction. The notation implies that SPEs A and B must 
bind to each other before C can bind to them. If A and B unbind, then there would 
no longer be an A:B for C to bind to. Therefore, SPE C must dissociate first 
before A and B can dissociate. The implicit complex SPEs shown in Figure 2 
does not provide readers of a MIM diagram information on the binding order of 
entities as the explicit complex representation. This representation is useful when 
binding order is unknown or when those details are not relevant to the intent of 
the diagram. 
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Since SPEs tend to exist once on a diagram, it becomes necessary to have a 
method for diagramming homo-dimerization interactions. Such interactions make 
use of restricted copy entities; small black dots that act as copies of the SPEs to 
which they are bound. Restricted copy entities cannot be included in any other 
interaction; the complexes resulting from homo-dimerization interactions can 
participate in interactions in the same way as other explicit complexes.  
 
Figure 3: Example of a trimer between simple physical entities A, B, and C. The 
explicit complex node on the binding interaction line between entities A and B denotes 
the dimer A:B and the binding interaction between this complex and C denotes the trimer 
A:B:C. 
 
There are two additional MIM entity glyphs: conceptual entity and source/sink 
glyphs. Conceptual entities, shown by a rectangular glyph, are capable of 
representing objects that do not have a clear physical structure (e.g. ionizing 
radiation) or where the physical structure is outside the scope of the given 
diagram. The source/sink symbol uses the mathematical symbol for an empty set 
and can be used to represent an unlimited and unspecified source for the 
production of an entity or an unspecified product of a degradation reaction. 
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2.2.4 Interaction Glyphs 
The notation has three categories of interactions that exist between entities: 
reactions (i.e. an interaction where the input and output are both entities), 
catalytic interactions (i.e. an abbreviation for a known set of reactions), and 
contingencies (i.e. an interaction in which a controller entity regulates, modifies, 
or otherwise influences another reaction or contingency). All the interaction 
glyphs are shown in Figure 1; for brevity, only the usage of a limited number of 
interactions is presented here. Readers are directed to the MIM specification for 
a description of all interaction types. The reaction types that exist include non-
covalent reversible binding, covalent modification, covalent irreversible binding, 
template reaction, stoichiometric conversion, and production without loss of 
reactants.  
 
Non-covalent reversible binding is represented as a double-headed line with 
barbed arrowhead endings connecting two entities; barbed arrowheads are 
permissible only in accordance with the specification rules outlined in Table 3 of 
the MIM specification in Appendix A. The outcome of an interaction represented 
by a non-covalent reversible binding glyph is an explicit complex, indicated by a 
filled circle on the interaction line; the resulting explicit complex can then 
participate in additional valid interactions.  
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Covalent irreversible binding functions in the same manner as non-covalent 
reversible binding, but with different semantics, namely that those interactions 
must be covalent and not directly reversible.  
 
Covalent modification uses a single-headed line with a barbed ending pointing 
towards the modified entity with a modifier entity on the end of the line that is not 
barbed, as shown in Figure 4.  
 
Figure 4: Formation of the phosphorylated entity A. Explicit complexes placed on the 
covalent modification lines represent the modified entity. 
 
Stoichiometric conversion uses a single-headed line with a triangle end that 
points from the reactant to the product. The stoichiometric conversion can be 
used to describe the production of multiple entities, as shown in Figure 5.   
 
 
Figure 5: Conversion of one entity into multiple entities. The stoichiometric 
conversion of entity A to entities B and C. 
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The MIM notation also offers glyphs to describe the stimulation and inhibition of 
other interactions, and these are part of the set of contingency interactions. An 
unfilled triangle arrowhead is used to represent stimulation, while a terminal bar 
is used for inhibition. To indicate that an entity is necessary for a process to 
occur, a bar is placed behind the unfilled triangle of the stimulation glyph.  
 
Catalytic interactions follow a similar set of syntactic rules as contingencies, but 
represent interactions requiring a catalyst (e.g. the enzymatic activity of a kinase 
or phosphatase). 
 
The MIM specification provides additional examples and guidance on the usage 
of the glyphs in the notation, especially in more complicated situations. 
 
2.2.5 Formal Rules for MIM 
One of the key features of this new implementation of the MIM notation is the 
introduction of a strict set of syntax rules that provide constraints on valid MIM 
diagrams. Previous MIM publications present both basic and elaborate 
examples, but did not codify the extent of the syntactic capabilities of the 
elements of the notation. There was no clear method to validate diagrams in 
terms of the manner in which elements are connected. The new syntax rules 
presented here will help users create and update valid MIM diagrams. 
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The syntax rules presented in Table 3 and Table 4 in Section 8.1 of the MIM 
specification in Appendix A treat each interaction glyph as having three possible 
places of connection: the start, the end, and the line itself. For symmetric 
interactions (e.g. non-covalent reversible binding and covalent irreversible 
binding), either terminus of the line may be considered the start of the interaction 
with respect to the syntax rules. For all other interactions types, the line terminus 
without an arrowhead is considered the start of the interaction. The syntax rules 
outline what entities may connect to the start or end of an interaction line or 
whether a symbol can exist on an interaction line between its termini. Additional 
rules in the formal MIM specification outline the usage of branching glyphs, as 
well as other syntactic rules.  
 
In addition to these rules, the MIM specification outlines how glyphs should be 
interpreted in conjunction with other glyphs. Section 8.4 of the MIM specification 
specifically outlines correct interpretations of the presence of entities given the 
potential incompleteness of knowledge about a particular entity based on the 
interactions in a diagram. This is closely aligned to the ideas of the "heuristic" 
MIM interpretation, which recognizes that the role of "transitive" effects (the effect 
of a given interaction on others) are often unknown (Kohn, Aladjem et al. 2006; 
Kohn, Aladjem et al. 2006). 
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2.2.6 Limitations of the Formal Implementation  
The MIM notation formalized by the current specification is constrained to 
facilitate the implementation of software tools for MIM, and does not include all 
MIM glyphs that have been published previously. In the notation's history there 
have been variations in the representation of certain glyphs; this issue has been 
addressed by choosing a single representation for each concept in the notation. 
This implementation of the notation also does not permit ad hoc glyph creation. 
This facilitates the validation of diagrams and allows software developers to be 
confident that they have implemented all known features of the implementation; 
other glyphs may be added in future releases of the specification.  
 
As the notation has evolved, several shorthand notation elements have been 
developed to simplify common patterns in MIM diagrams. The current 
implementation provides a limited number of these shorthand notation elements 
from previous MIM publications. Undoubtedly, this means that certain constructs 
in diagrams will be more visually complex, but since these elements do not add 
to the semantic capacity, they have been postponed for future releases.   
 
The specification presented here does not provide strict guidance on the glyphs 
of the notation that are suitable for computational simulations, though this topic 
has been discussed previously regarding MIMs, and MIMs have been used in 
conjunction with mathematical simulations (Kohn, Aladjem et al. 2006; Kim, 
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Aladjem et al. 2010). One future development that may support such a goal is by 
outlining an additional validation method for glyphs appropriate in computational 
simulations. 
Lastly, this implementation does not specify a notation to represent transport 
interactions. Entities in the MIM notation may represent a given entity in multiple 
states (e.g. a protein with some molecules in the nucleus and others in 
cytoplasm). With no clear way of distinguishing these states, the semantics of a 
transport interaction would be unclear; this is a problem common to other similar 
notations such as the SBGN ER notation (Le Novère, Moodie et al. 2010). In 
previous MIM publications, transport reactions have been represented by a 
stoichiometric conversion glyph. In many cases this representation is clear and 
unambiguous. That representation, however, sometimes introduces awkward 
ambiguities. Therefore, we did not include transport reactions in the current 
version of the formal MIM specifications. 
 
2.2.7 Current Machine-Readable Representations of MIM Diagrams  
Several software projects have included support for the notation and have each 
addressed the lack of a standardized data model for the MIM notation differently. 
The first associated software project for MIM diagrams integrated the diagrams 
with metadata in the form of E-MIMs (electronic MIMs) found at 
http://discover.nci.nih.gov/mim (Kohn, Aladjem et al. 2006). E-MIMs store the 
diagrams using the SVG (Scalable Vector Graphics) format to provide interactive 
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features allowing the graphic elements to be connected to metadata. The SVG 
format does not retain the semantics of the elements visualized and, the 
metadata, currently, are reintroduced to the SVG files through a post-processing 
step. 
 
Another project, the Java-based biological pathway diagram editor PathVisio, 
(van Iersel, Kelder et al. 2008) includes the glyphs of the notation to facilitate the 
production of MIM diagrams. The PathVisio software provides MIM-specific 
interaction glyphs for diagrams that are stored using the GPML (GenMAPP 
Pathway Markup Language) format. The MIM-specific glyphs are provided as 
additions to the pre-existing PathVisio glyphs that are external to the MIM 
notation. If users include both MIM-specific and external glyphs, the diagram will 
be viable in the context of the GPML format, but will lose the consistency 
required for exchange with other MIM-specific tools and tasks, such as validation.  
 
Software support for MIM was recently provided by the MIMCITY database 
project (http://www.mimcity.org) for storing, querying, visualizing and analyzing 
data contained in MIM diagrams (Karac, Ozturan et al. 2010). The project 
developed an accompanying data model implemented in the form of a database 
schema that is compatible with an SBML-based representation of the MIM 
notation also developed for the project. The SBML-based MIM representation 
addresses incompatibilities between the MIM and SBML through the use of 
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SBML annotation containers to embed MIM information content not supported in 
SBML. The MIMCITY database schema and the SBML-based MIM 
representation, however, do not include elements to describe the visualization of 
MIM diagrams.  
 
2.2.8 Overview of MIM Schema 
The various formats used in the aforementioned projects have limitations that 
highlight the need for a standard format to support future MIM software projects. 
The new MIM Markup Language (MIMML) meets this need and provides a 
standard format for the exchange of MIM diagrams among different software. 
The MIMML format conforms to XML Schema 1.0, and is based on the GPML 
schema developed for use with PathVisio (Bray, Paoli et al. 1998; van Iersel, 
Kelder et al. 2008). MIM datasets are plain-text XML data streams: the datasets 
are characterized by matching start and end tags, and elements can contain 
attribute-value pairings. The schema is used to store information about the visual 
presentation (e.g. positioning, color, or size) and layout of the diagram as well as 
accompanying metadata (relationships to external databases, annotations, and 
citations).  
 
The MIMML format employs several XML elements of different types; the ones of 
most importance are outlined here. The root element of the MIMML schema is 
the Diagram XML element used primarily to store size information about the 
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diagram. This element can have several types of child elements; primarily these 
include: EntityGlyph, InteractionGlyph, Anchor and MimBio XML elements; 
Figure 6 shows a small MIMML dataset that includes examples of all the MIMML 
elements described; other example files on the website have more 
comprehensive examples (http://discover.nci.nih.gov/mim). EntityGlyph is used to 
store information about all MIM entities. This is a departure from GPML, which 
stores information in implicit and explicit complexes as groups and anchors, 
respectively. This change allows for a uniform mechanism when validating MIM 
entity glyphs. InteractionGlyphs are used to store information about interactions 
and the elements to which they are connected. An InteractionGlyph XML element 
is made up of several Point elements. Point elements provide routing information 
and store type of arrowheads used in a given interaction as shown in Figure 6. 
For the purposes of validation, the MIMML schema, unlike GPML, restricts the 
types of arrowheads that can be used to only those that exist in the MIM notation. 
The first and last Points of an InteractionGlyph contain the visRef attribute to 
specify to which MIM element each line end is connected; shown in Figure 6. 
InteractionGlyphs may also include attributes pointing to Anchor XML elements. 
Anchors are connection points on an InteractionGlyph. These are used to 
connect interactions to each other, as is the case with contingencies, and also, to 
represent the intramolecular glyph on an interaction.  
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Figure 6: Example MIMML dataset that describes the interaction of the cleavage of 
phosphate from CaMK. Blue: Highlighted section describes graphical elements of the 
MIM notation. Red: Highlighted section describes metadata components of the MIM 
notation including diagram title and identifier and a publication cross-reference. 
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The XML elements for interactions and entities can also include references to 
particular metadata items stored in the MIMBio XML element that acts as the 
primary location for the storage of MIM metadata. The MIMML format supports 
two types of metadata: cross-references and annotations. Cross-references allow 
the mapping of external database resources to MIM elements. Annotations exist 
as two components: a comment and a publication cross-reference. This allows 
users to map particular interactions to the publications that provide evidence for 
the existence of the interaction, while the comments stored for specific MIM 
elements provide additional information about entities and interactions not 
captured by the notation. The structure of MIM cross-references is modeled after 
those in the BioPAX format (Demir, Cary et al. 2010). The MimBio XML element 
also stores metadata related to the diagram, such as title and creator information; 
these elements are similar to those provided in GPML with the exception that 
they use terms from the Dublin Core set of metadata terms 
(http://dublincore.org/).  
 
The MIMML schema adds additional metadata elements to allow controlled 
vocabulary to be used to describe the relationship of an external database 
resource and a MIM element and to allow users to specify the biological 
properties of entities through controlled vocabulary beyond the generic 
terminology used by the MIM notation (e.g. a simple physical entity can be 
described as a protein, DNA, RNA, etc). The values for element type were 
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adopted from the BioPAX format to simplify the process of translating MIM 
diagrams to BioPAX datasets.  
 
2.2.9 An Example Diagram and MIMML Dataset  
In this section, we provide an example of the MIM notation and MIMML format 
with the use of the Ca2+/calmodulin-dependent protein kinase (CaMK) MIM 
diagram (shown in Figure 7) stored in the MIMML format available on the project 
website (http://discover.nci.nih.gov/mim). The CaMK regulation MIM was 
originally introduced in the 2006 specification of the MIM notation as Figure 12 of 
that publication; a full description of the interactions is included by Kohn et al 
(Kohn, Aladjem et al. 2006). The diagram covers many of the properties of the 
MIM notation, thereby making it useful when describing the changes that have 
been made to the MIM notation. The CaMK example shows the intramolecular 
control of the protein kinase CaMK, and how this regulation can affect the 
phosphorylation of substrates (labeled here as "Various substrates") by the 
kinase domain of CaMK. Figure 7 shows the diagram according to the formal 
MIM presented here. The most significant visual change is in the CaMK protein 
glyph. The entity glyph for the CaMK protein is linked to its two domains (the 
kinase and regulation domains), and the domains have been separated so they 
exist in two separate entity feature glyphs. The cleavage and intramolecular 
glyphs have undergone cosmetic changes, as well as the way that branched 
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interactions are supported. Changes to the diagram are largely cosmetic to 
simplify the implementation of the notation in software editors of MIM diagrams. 
 
 
Figure 7: CaMK MIM diagram based on the specification outlined in the current 
publication.  
2.2.10 Validation of MIM Datasets  
Datasets for each schema are validated at two levels: the first is with regard to 
the well-formedness of the dataset according the MIMML XML schema and the 
second are rules that are outlined in the formal MIM specification. The MIMML 
XML schema outlines the valid structure of a MIMML dataset, which can be used 
for validation purposes. The second level of rules checks proper usage of several 
properties of MIMML datasets: use of entity/interaction attributes, formats of 
labels for modifiers and entity features, use of interaction arrowheads, placement 
of explicit complex and intramolecular symbols, and connection of interactions to 
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entities or other interactions. Validation of MIMML datasets against the formal 
MIM connection rules is done using Schematron, a rule-based validation 
language for finding patterns in XML trees (Jelliffe 2006). Assertions about the 
presence or absence of these patterns can be used to determine that a 
document adheres to a given rule set. Currently, MIMML datasets are not being 
validated against the layout rules and recommendations found in the formal MIM 
specification; the focus here is to validate the syntax of MIM diagrams. 
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Figure 8 illustrates a rule for a MIMML dataset that determines whether explicit 
complexes in a given MIM diagram were placed on the correct types of 
interactions; these interaction types include: covalent modification, non-covalent 
reversible binding, covalent irreversible binding, and state combinations. Results 
from validation are returned in the Schematron Validation Report Language 
(SVRL), a simple report XML-based language 
(http://www.schematron.com/validators.html). The results provide the name of 
the rule fired, the elements tested, the rule tested, the location of elements failing 
the test using an XPath expression, and diagnostic information relevant to invalid 
elements.   
 
 
Figure 8: A Schematron-formatted rule validating the placement of explicit 
complex glyph within a MIMML dataset. Blue: The context to which the set of rule 
assertions refer; in this case, entity glyphs of type "explicit complex". Red: Assertions 
related to the context XML element. In this case, an explicit complex may only exist on 
interactions of the following types: covalent modification, non-covalent reversible 
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binding, covalent irreversible binding, and state combination. Green: A set of diagnostic 
entries to be displayed, if the test assertion fails, including the ID of the explicit complex 
glyph (vis-id), the ID of the interaction on which the explicit complex appears (inter-vis-
id), and the types of arrowheads at the start and end of the interaction glyph (inter-start-
arrowhead and inter-end-arrowhead). 
 
The MIM Schematron rule set can be used wherever Extensible Stylesheet 
Language Transformations (XSLT) may be used with other standard XML tools. 
To simplify the use of the Schematron rule set, it is made available in conjunction 
with Java-based Schematron Ant Task (http://code.google.com/p/schematron/) 
along with a Java build file to show how Schematron may be used as a part of a 
pipeline and for the batch validation of multiple MIMML datasets.  
 
2.2.11 MIM Application Programming Interface (API) Implementation  
Usage of an XML-based format to store the data of MIM diagrams allows 
developers to provide MIMML-related functionality using commonly available 
libraries capable of parsing XML data streams, but these libraries work at a low-
level; that of XML elements and attributes. The MIM API provides a higher-level 
of functionality to interact directly with features of the MIMML schema.  
 
The MIM API is Java-based API to the elements and attributes for the 
manipulation and retrieval of information contained in a MIM diagram set forth by 
the MIMML XML schema. The interface is generated using XMLBeans 
(http://xmlbeans.apache.org/) a Java-to-XML binding framework used for 
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developing Java applications built around an XML schema. The framework 
provides wide coverage of the features available for XML Schemas and maps 
XML data types to Java data types. XMLBeans generates a set of corresponding 
Java classes based on an input XML Schema. These generated interfaces and 
classes can then be used by developers to access and manipulate XML instance 
data using JavaBeans-style accessors (e.g. getFoo() and setFoo()), which are 
more friendly than usage of the XML Document Object Model (DOM). XMLbeans 
provides an XML parser and validator, and gives developers the capability of 
lower-level navigation of an XML document using XMLCursor. A complete 
description of XMLBeans is available at 
(http://xmlbeans.apache.org/documentation/index.html). The MIM API requires 
the installation of the underlying XMLBeans library (http://xmlbeans.apache.org). 
The XMLBeans library provides support for XPath and XQuery expressions using 
the Saxon XSLT and XQuery processor (http://saxon.sourceforge.net). 
 
2.2.12 Usage of the MIM API 
Operations using the API are aligned to the MIM XML schema, and one Java 
object corresponds to each element in the MIMML document. All of the interfaces 
to the MIM elements inherit from the XMLObject interface, provided by 
XMLBeans. This interface provides basic functionality for all objects, such as the 
method for validation against the XML schema. Usage of the XMLBeans library 
provides the capability of inputting MIMML files in a variety of ways including 
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from a file or string, but the MIM API is also capable of importing from a Java 
XML DOM (Document Object Model) Node object or by retrieving a MIMML data 
stream using a URL (Uniform Resource Locator). MIMML datasets can also be 
created de novo and existing datasets can be manipulated. The MIM API 
supports all the constructs of the MIMML format including the ancillary 
constructs, such as comments, and generic properties. Using a Java-based 
XSLT processing engine, such as Saxon, it is possible to additionally validate 
MIMML datasets against the Schematron rule set within a Java program.  
 
2.2.13 Benefits/Disadvantages of XMLBeans for the MIM API 
The MIM API can be used in conjunction with APIs for other formats or libraries 
providing other functionality, but the major distinction between the SBML and 
CellML APIs and the MIM API is the usage of an XML-binding framework, which 
comes with both benefits and disadvantages. One benefit is that the usage of 
XMLBeans has simplified and sped up the development of a MIM API. This has 
allowed it to reach its intended audience faster, which allows developers to 
concentrate on developing applications that support the MIM notation and make 
use of the information content represented by the diagrams rather through 
manual generation of boilerplate code. Secondly, there is the minimization of 
bugs due to the stability of the XMLBeans code base resulting from over five 
years of development and use. Lastly, maintainability is improved through code 
generation that aids in the adaption of software to future changes made to the 
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underlying MIM schemas. A disadvantage in the usage of XMLBeans is that it 
provides functionality for a single programming language, which may be a 
deterrent to some developers. Both SBML and CellML provide several language 
bindings (Bornstein, Keating et al. 2008; Miller, Marsh et al. 2010). As the need 
for the support of other languages increases, other XML-binding libraries will be 
used to make these language bindings available. 
 
2.3 Discussion 
The Molecular Interaction Map (MIM) notation provides a way to depict 
bioregulatory network diagrams in a standardized manner. The notation was 
originally developed in 1999 and has since been further developed and updated, 
most notably in 2006 (Kohn 1999; Kohn, Aladjem et al. 2006), where a detailed 
description of the glyphs and their usage was provided. The MIM notation has 
been developed in a fluid manner that has allowed it to depict a wide range of 
biological concepts including notation for polymerase, helicase, and primase 
activity as well as other symbols (Kohn, Aladjem et al. 2008). These fluid 
advancements in the notation enhance the range of biological networks that can 
be diagrammed, but can hamper the development of consistent software for the 
MIM notation. Here we present a well-defined and internally consistent MIM 
formalism and set of tools that can facilitate the development of software 
supporting the major parts of the MIM notation in the areas of creation, validation, 
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and analysis of MIM diagrams. These tools should also facilitate the translation of 
MIMML-formatted diagrams to and from other formats, such as the BioPAX or 
the Systems Biology Graphical Notation Markup Language (SBGN-ML) format 
currently in development (http://libsbgn.sf.net/). SBGN-ML and other 
developments by the libSBGN group will provide developers with tools similar to 
the ones we present here for MIM, so that pathway editors, such as 
CellDesigner, Edinburgh Pathway Editor, PathVisio, and VANTED, can support 
SBGN in a common manner (Funahashi, Tanimura et al. 2003; Junker, Klukas et 
al. 2006; Sorokin, Paliy et al. 2006; van Iersel, Kelder et al. 2008).  
 
A MIM diagram editor, MIMTool, has been developed, which supports the 
MIMML format presented herein (http://code.google.com/p/mimtool/). It is limited 
in that it does not yet support the metadata components of the format. MIMTool 
is associated with the MIMCITY database for MIM diagrams, which is expected 
to also support the MIMML format in the future (http://www.mimcity.org) [23]. 
Additionally, PathVisio (http://www.pathvisio.org) is in the process of being 
extended to support the MIM specification and the MIMML schema; one key 
feature being added to PathVisio is the ability to render MIMML files. The 
example figures associated with the current publication have been produced in 
PathVisio (Luna, Sunshine et al. 2011).  
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The current work places a major emphasis in providing developers basic tools to 
facilitate software development, and enhances the level of detail for the 
presentation of MIM concepts. It is hoped that this new level of detail simplifies 
the adoption of additional MIM concepts into the SBGN notations or other 
notations. As one example, MIMs can represent protein domains as entity 
features, and this capability is important for the depiction of many critical 
biological signalling pathways. Interactions involving domains can therefore be 
represented with greater flexibility using MIMs than with SBGN ER, which 
currently does not address domain representation (Le Novère, Moodie et al. 
2010). For an example of how SBGN addresses interactions involving the 
domains represented in MIMs, the reader might compare Figure 7 for CaMK 
regulation in the current text with Figure 2.1 in the SBGN ER specification. While 
graphical notations in biology have received strong attention in recent years, no 
notation has yet met all the needs of users. One of the most recent MIM 
publications (Kohn, Aladjem et al. 2008) outlines the depiction of several new 
glyphs for polymerase, helicase, and primase activity, which helps to further the 
discussion on use cases still requiring a standardized depiction. 
 
As the usage of new components of MIM notation become clarified, we plan to 
add them to the specifications and to the MIMML schema. Additionally, the 
combinatorial interpretation mode of MIM diagrams (Kohn, Aladjem et al. 2006) is 
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in the process of being algorithmically defined and will be supported in future 
software.  
 
The work presented here makes advances in the usage of the MIM notation to 
visualize data in a way that is more "natural" to humans while retaining the 
qualities of being consistent and machine-readable. Participation by software 
developers within our group and collaborators has helped to ensure that all 
elements have a straightforward implementation. This implementation of the MIM 
notation will continue to expand to cover more of the glyphs outlined in 
publications on the MIM notation; each acting as a basis for the development of 
MIM software support.  
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3 MIM SOFTWARE 
3.1 PathVisio-MIM: PathVisio plugin for creating and editing 
Molecular Interaction Maps (MIMs) 
(Note: Section taken from:  
Luna A, Sunshine ML, van Iersel MP, Aladjem MI, Kohn KW. PathVisio-MIM: 
PathVisio plugin for creating and editing Molecular Interaction Maps (MIMs). 
Bioinformatics. 2011 Aug 1;27(15):2165-6.; Luna A contributions: Coded the 
conversion the GPML to MIMML along with export functionality, minor GUI edits, 
helped write and edit manuscript and documentation and respond to reviewer 
comments) 
 
3.1.1 Introduction  
Understanding biological pathways requires knowledge of both the biological 
components of a pathway and the interactions between its components. 
Improvements in molecular biology techniques have fueled a surge in this type of 
information, which has made the organization of biological knowledge an 
imperative along with consistent mechanisms for how this information is ex-
changed amongst researchers.  
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One of the most common means of relating information about biological 
pathways is through the use of pathway diagrams which are oftentimes more 
"natural" to readers. The Molecular Interaction Map (MIM) notation is a graphical 
notation for depicting diagrams of biochemical and cellular processes meant to 
alleviate ambiguity that exists in many diagrams currently found in publications 
(Kohn, Aladjem et al. 2006). Diagrams using the MIM notation are similar to road 
maps or electronic circuit diagrams for defining entities and their interactions in 
biological systems.  
 
The MIM notation has been described extensively in the past, but until now there 
has been only limited software support for the notation. Software support is 
important to make the development of large-scale diagrams typical to MIM 
diagrams feasible. Previously, creation of MIM diagrams was conducted using 
general graphics products, such as Adobe Illustrator and ACD Canvas. Some 
missing features in these tools include easy access for new users to MIM glyphs, 
connectors that remain attached to elements as they are rearranged, connectors 
with routing capability, and functionality to associate annotations to specific 
elements.  
 
PathVisio is a full-featured diagram editor for biological pathways with the ability 
to change many attributes of diagram elements: data nodes (color, size, and 
labels) and connecting lines (color and arrowheads) (van Iersel, Kelder et al. 
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2008). PathVisio also allows elements to be linked to external databases and 
references, and it is capable of producing graphics in a variety of formats 
including SVG, PNG, and PDF. PathVisio is a Java-based application that makes 
it available on all major computing platforms (e.g. Windows, Mac OS X, and 
Linux). Additionally, Path-Visio has provided some of the graphical elements 
necessary for the MIM notation since PathVisio 1.1. 
 
Since these earlier versions, continued development of the MIM support has 
been conducted as an independent plugin. By moving MIM functionality into a 
plugin, the user-interface can be highly customized to MIM support, while the 
core program remains open to unformatted pathway diagrams. The major 
objective of this project is to provide complete support for the MIM notation in a 
simple to use graphical editor and for it to serve as one starting point for future 
MIM software development. 
 
3.1.2 Implementation and PathVisio-MIM Features 
The MIM notation has evolved, since its inception in 1999, as it has become 
necessary to support additional biological constructs. An updated specification 
(available at http://discover.nci.nih.gov/mim/) was recently created that is meant 
to facilitate software implementation; readers should refer to Luna et al. 2011 for 
information regarding the MIM glyphs as implemented in this plugin (Luna, Karac 
et al. 2011). The Path-Visio-MIM plugin provides the following features:  
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Entity and Interaction Glyphs: The plugin introduces a new side panel that 
contains the MIM glyphs separated into the categories laid out by the 
specification; these are shown in Figure 9. Interaction glyphs drawn through this 
interface use orthogonal line connectors that are recommended for MIM 
diagrams.  
 
 
Figure 9: Screenshot of PathVisio diagram editor with PathVisio-MIM plugin 
loaded. MIM-specific glyph are shown in the right-hand side panel. 
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Additional MIM Glyphs: Support for the additional MIM glyphs, such as 
complexes, branching connectors, and the glyph representing intermolecular 
interactions are provided through user interactions outside the MIM panel; for 
instance, the product of a binding interaction added through the right-click menu. 
Instructional videos are provided for usage of these glyphs. 
 
Annotations: Interactions on diagrams may be annotated with comments and 
literature reference information. These annotations allow users to document the 
sources of interactions and help readers of MIM diagrams find the original 
resources to gain a greater understanding of a particular biological system. 
Additionally, entities may be cross-referenced with identifiers from a wide range 
of external databases, such as Entrez Gene, HUGO gene names, etc. 
 
Support for MIMML: An exchange format, the MIM Markup Language (MIMML), 
was recently developed for the notation. The format is intended as a common 
exchange mechanism between MIM software, and is supported by another MIM 
editor, MIMTool (http://code.google.com/p/mimtool/). Additionally, this format is 
used for the validation of MIM diagrams according to syntax rules outlined by the 
MIM specification. Import and export functionality in the plugin is provided 
through a MIM application programming interface (API); export functionality only 
exports MIM-specific elements (Luna, Karac et al. 2011). One potential use of the 
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import capability is for loading MIMML documents from other tools for conversion 
into other formats that PathVisio supports. 
 
3.1.3 Discussion 
The PathVisio-MIM plugin helps biologists draw diagrams in accordance with the 
Molecular Interaction Map (MIM) notation, this combined with the many features 
of PathVisio will aid in making the MIM notation accessible to a wider audience. 
To encourage usage of this software and the notation by first-time users, we 
provide example files, written documentation, and instructional videos on the 
project website. 
  
The plugin takes advantage of the extensible nature of PathVisio to provide 
support of all the major features of the MIM notation and supports the MIMML 
format used by other MIM editors, such as MIMTool 
(http://code.google.com/p/mimtool/). Code additions that were made in the core 
PathVisio editor should facilitate the support other graphical notations in 
PathVisio, such as the Systems Biology Graphical Notation (SBGN) or the 
modified Edinburgh Pathway notation (Le Novère, Hucka et al. 2009; Freeman, 
Raza et al. 2010); support for the SBGN notation is currently in development via 
a separate PathVisio plugin. Support for these notations or other notations within 
the same software tool, Pathvisio, presents a basis for translating diagrams 
between notations. Future development of the plugin is expected as additions are 
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made to the MIM specification. Also, we expect the addition of validation support 
in PathVisio for rulesets, such as the one developed for MIMML. This feature will 
be similar to syntax validation found in many integrated development 
environments (IDEs) used by programmers.  
 
3.2 PathVisio Validator: A Rule-based Validation Plugin for 
Pathway Graphical Notations 
(Note: Section taken from:  
Chandan K, van Iersel MP, Aladjem MI, Kohn KW, Luna A. PathVisio Validator: 
A Rule-based Validation Plugin for Pathway Graphical Notations. Bioinformatics. 
2012 Mar 15;28(6):889-90.; Luna A contributions: guidance on project scope and 
usage of incorporated libraries; programmed all incorporated rulesets both in 
Schematron and Groovy; helped write and edit manuscript and documentation 
and respond to reviewer comments; project maintenance after publication) 
 
3.2.1 Introduction 
Biological researchers use pathway diagrams as the medium to relay information 
about interactions among biological entities. Graphical notations like the 
Molecular Interaction Map (MIM) notation and the Systems Biology Graphical 
Notation (SBGN) promote the creation of unambiguous biological pathway 
diagrams through the use of well-defined rules for syntax. The specifications for 
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these notations are long and technical, and this is a barrier to the wider usage of 
these notations by researchers. This issue presents a clear need not only for 
tools that simplify the usage of these graphical notations, but also tools that guide 
users in their correct usage. 
 
PathVisio is an open source Java-based tool for creating and editing biological 
pathways, and linking diagram elements to external bioinformatics databases 
(van Iersel, Kelder et al. 2008). By itself, PathVisio does not compel users to 
create diagrams using any particular notation; support for specific notations is 
added through the use of plugins, such as the MIM plugin (Luna, Sunshine et al. 
2011) or the SBGN plugin (http://www.pathvisio.org/wiki/SbgnPluginHelp). Given 
this open nature of PathVisio, we have developed a validation framework similar 
to what developers are accustomed to in source code editors that report syntax 
errors. This accommodates the validation of pathway diagrams against any 
notation that PathVisio can draw, with just the click of a button.  
 
There are several projects related to standardized formats for computational 
biology that have associated validators. These include well-known formats like 
BioPAX (Demir, Cary et al. 2010) and SBML (Hucka, Finney et al. 2003), and the 
validation capability in SBGN-ED (Czauderna, Klukas et al. 2010), an SBGN 
diagram editor. The plugin also shares characteristics with generic XML editors 
with validation capability, such as XML ValidatorBuddy for XMLSpy (http://xml-
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tools.com/ValidatorBuddy.htm). A key difference between SBGN-ED and the 
plugin presented here is the extensible support for other notations in the latter, 
which is especially important for the PathVisio community since its users may be 
using various graphical notations for specific purposes. The second difference is 
that rulesets (specifically, Schematron rulesets) created for use with this plugin 
can be reused in other software projects.  
 
3.2.2 Implementation 
The validation of pathways using the plugin is done based on a ruleset (a 
collection of rules). The plugin allows users to use their own custom created 
rulesets, or standard rulesets by notation developers. Described below are the 
main features of the Validator plugin and its user interface: 
 
Plugin Interface and Current Notation Support: The interface for the plugin 
exists under the "Validator" tab of PathVisio as shown in Figure 10. At the bottom 
of the tab are buttons for loading a ruleset and validating the current diagram. In 
order to validate a pathway diagram, the user just has to choose a ruleset and 
press the “Validate” button. Validation messages for the current pathway diagram 
will then appear in the side-panel as shown in Figure 10. These messages can 
be filtered to show only errors, only warnings, or both, using a drop-down menu. 
At the top, a count for errors and warnings is provided and an option to select a 
specific rule group for validation. Using right-click options, users can ignore 
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particular messages or types of messages. Currently, the plugin supports the 
MIM notation through a Schematron ruleset. Also, a ruleset used in the curation 
of diagrams on the WikiPathways database (http://wikipathways.org), a 
repository for biological pathway diagrams, is also included with the plugin. 
Support for SBGN is expected when PathVisio SBGN support is completed. 
 
 
Figure 10: Screenshot of the PathVisio-Validator plugin. A pathway diagram being 
validated using the PathVisio-Validator plugin. 
 
Schematron and Groovy Ruleset Support: The plugin supports rulesets 
written either in Schematron or Groovy. Schematron 
(http://www.schematron.com) is an XML validation language that uses XSL 
Transformations (XSLT). The result of validation is a simple XML formatted 
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report using the Schematron Validation Report Language (SVRL). This validation 
report is parsed and error or warning messages for the current diagram are 
displayed in the “Validator” tab as shown in Figure 10. 
 
An advantage in using Schematron rulesets is that validation support can be 
added, using the same ruleset, in any software project where an XSLT processor 
is accessible. Schematron validation works according to the following procedure: 
First, the current diagram is exported in the background to a format appropriate 
for the ruleset. For instance, MIM diagrams are exported to MIMML when using 
the MIM Schematron ruleset (Luna, Karac et al. 2011). This step makes the 
diagram amenable for XSL trans-formation. Secondly, the ruleset is transformed 
against an SVRL skeleton file to produce an XML stylesheet (XSL). Lastly, the 
XML output of step 1 is transformed using the XSL from step 2 to generate an 
SVRL report, which is then parsed to produce validation messages in the plugin’s 
panel. These XSL transformations are done using SAXON 
(http://saxon.sourceforge.net), an XSLT and XQuery processor. 
 
Groovy (http://groovy.codehaus.org) is a dynamic language with syntax similar to 
Java. Creating rulesets in Groovy is easy for users with a basic understanding of 
Java. Groovy rules are basically a collection of methods with specific signature 
for them to be recognized as valid rules. These are run directly against the 
internal memory representation of the diagram in PathVisio, producing results in 
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the form of strings, which are then parsed and displayed on the plugin's panel. 
Validation against a Groovy ruleset, consumes less time than its Schematron 
counterpart, since it does not require any XSL transformations to take place. 
However, the downside to this approach is that the Groovy rules are tied to the 
internal workings of PathVisio. An example of rule checking for unattached lines 
is provided in both Schematron and Groovy on the project website along with 
detailed information on creating rulesets. 
 
Support for Validation based on Rule Groups: Validation rules in rulesets may be 
put into groups. Thus, validation can occur using all the rules in a ruleset or only 
those under a specific group, thereby making it more selective. Schematron 
supports rule groups using the "phase" XML tag with one or more "active" rules 
as child XML nodes. And Groovy supports it through a specific method that 
defines all the supported rule groups and their associated rules. 
 
3.2.3 Conclusion 
The PathVisio Validator plugin has been developed to enhance the quality of 
pathways created in PathVisio by assisting biologists who diagram pathways 
according to specific graphical notations. Validation of this nature allows 
researchers to be more confident that their diagrams will not be ambiguous to 
readers. The extensible nature of the rulesets should allow it to adapt to 
preferences of PathVisio users. Moreover, this plugin will also encourage the 
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users of PathVisio, especially the beginners to create pathways based on 
specific notations, such as MIM or SBGN. And the support for different ruleset 
formats (i.e. Schematron and Groovy) should allow users to create rulesets 
based on their priorities.  
 
In the future, we plan to extend this validation concept to WikiPathways (Pico, 
Kelder et al. 2008), so that all the uploaded/updated pathways on it are validated 
against some common rules. Another future addition would be to include a real-
time validation support where diagrams are validated continuously in the 
background. 
 
3.3 PathVisio-Faceted Search: An Exploratory Tool for Multi-
Dimensional Navigation of Large Pathways 
(Note: Section taken from:  
Fried J, van Iersel MP, Aladjem MI, Kohn KW and Luna A. PathVisio Faceted 
Search: An Exploratory Tool for the Multi-dimensional Navigation of Large 
Pathways. Bioinformatics. 2013 Apr 1.; Luna A contributions: guidance on project 
scope and usage of incorporated libraries; helped code the webservice 
mechanism; created all the test examples and data; coded all Groovy scripts; 
added code to handle exception cases for both local data and webservices; 
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minor GUI edits; added export functionality; helped write and edit manuscript and 
documentation and respond to reviewer comments) 
3.3.1 Introduction 
Pathway diagrams are important tools that facilitate understanding biological 
systems by aggregating many disparate observations into concise 
representations. There is a growing trend to use formal graphical notations, such 
as the Molecular Interaction Map (MIM) notation and the Systems Biology 
Graphical Notation (SBGN), to display greater mechanistic detail about pathway 
inter-actions than is typical in protein-protein interaction networks (Le Novère, 
Hucka et al. 2009; Luna, Karac et al. 2011). There are well-known tools in this 
area such as Cytoscape that possess powerful annotation and search 
capabilities (Smoot, Ono et al. 2011). But Cytoscape is focused on network 
analysis, not diagram rendering, and as such misses capabilities necessary to 
render diagrams that are fully compliant with MIM or SBGN. The CySBGN plug-
in is the current best attempt, but has notable rendering issues 
(http://www.ebi.ac.uk/saezrodriguez/cno/cysbgn/). 
 
PathVisio (http://pathvisio.org/) is a free, open-source tool built to display and edit 
diagrams using formalized notations (van Iersel, Kelder et al. 2008). PathVisio 
also has the important capability of visualizing microarray and metabolomics 
data, but lacks other search features including the visualization and search of 
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nominal data, limiting analysis, especially on the growing number of pathways in 
the related WikiPathways database (Pico, Kelder et al. 2008).  
 
Here we present a robust search plugin for PathVisio using the faceted search 
method, which is found on e-commerce websites to search for products using 
discrete attributes known as facets. Entries in various facets can be selected to 
filter down to content of interest. Faceted searching is found in a variety of 
bioinformatics tools, including the Protein Data Bank (http://www.rcsb.org/). 
Facets allow users to attach additional data to pathways using biological 
identifiers. Any piece of data that can be looked up in a database based on an 
identifier such as "HGNC: TP53" can be used as a facet and searched. For 
example, a user might wish to know whether particular proteins in a pathway are 
involved in cell division, are known targets of the cancer drug, doxrubicin, and/or 
are over-expressed in an experiment. The faceted search PathVisio plugin allows 
users to easily ask complex queries of biological pathways and identify biological 
entities of interest through the powerful search capability on user data, data 
webservice data, and data processed using its scripting capability. 
 
3.3.2 Implementation 
The plugin interface, pathway compatibility, and dataservice options are 
described below: 
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Plugin Interface: The plugin’s interface is found in the “Facets” pane of the 
PathVisio sidebar; Figure 11 shows a pathway with three facets added using 
data from Ensembl: 1) Transcript count, 2) Pathology, and 3) Chromosome 
Name. The main area of the sidebar is the location that the added facets will 
appear. At the bottom, there are buttons for managing dataservices and adding 
facets. There are two types of facets: string and numeric. String facets are for 
nominal data (e.g. cellular location, molecular function, etc.) where entries for 
each category present in the dataset are displayed; these can be searched via 
the text field on the top-right of each facet. Numeric facets perform a numeric 
comparison (equal to, less than, or greater than) between a user provided value 
and the values in the dataset. This facet returns a Boolean response or error in 
the case of an unsuccessful comparison. All facet entries have an appended 
count reflecting the number of nodes satisfying the particular condition, and 
clicking on an entry will highlight all diagram nodes satisfying the conditions of all 
the facets. 
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Figure 11: Screenshot of the Faceted Search plugin. The Faceted Search plugin 
used to identify genes with a select number of variants, related to lymphomas, and 
located on specified chromosomes resulting in two highlighted nodes. 
 
Compatible Pathways: The PathVisio-Facet Search plugin can operate on any 
pathway loaded into PathVisio, including those on WikiPathways, but the plugin 
only functions on those data nodes that have been annotated with database 
identifiers. This is a key requirement for connecting imported data to the 
identifiers on the diagram. Many database providers use unique identifier 
schemas for the same biological entities, thus requiring ID mapping to translate 
between the different identifier formats. BridgeDb is used as a mapping service; 
to function properly an organism must be specified for a pathway (van Iersel, 
58 
 
 
Pico et al. 2010). The BridgeDb service works either through a local database 
loaded in PathVisio or the BridgeREST API.  
 
Available Dataservices: There are three types of data sources (dataservices) 
that can be used with the plugin: 1) local files formatted as Tab Separated Values 
(TSV) or Comma Separated Values (CSV) files, 2) the Ensembl BioMart 
webservice, and 3) Groovy scripts.  
 
Local Files: TSV/CSV files can be added as dataservices. Each file row should 
map to a node on a diagram and each column is a facet entry. The first file row 
should be headers describing the column contents (HGNC Symbol, Molecular 
Weight, etc.) and are used as the facet titles. At least one column must contain 
identifier information; the identifier column and its identifier type, is specified in 
the "Manage Dataservices" dialog.  
 
Ensembl Webservice: Ensembl BioMart (http://www.biomart.org/) is a free 
webservice that provides the ability to query multiple biological databases 
through a single interface (Guberman, Ai et al. 2011). This dataservice is built-in 
to the plugin, and can be enabled or disabled. A subset of approximately 70 
Ensembl attributes is available through this dataservice; the remaining attributes 
are available through the plugin’s scripting functionality. Turning on the 
dataservice adds all of the available attributes to the "Add Facet" dialog. Adding 
59 
 
 
a facet from Ensembl may take some time as all of the data must be downloaded 
from their servers. 
 
Groovy Scripting: This dataservice type provides the most flexibility of the three 
by incorporating Groovy (http://groovy.codehaus.org), a scripting language that 
can be embedded in Java applications. Groovy may be used to perform 
additional logic, to incorporate and pre-process other data formats, and access a 
greater variety of webservices. These are added by clicking "Add Groovy" in the 
"Manage Dataservices" dialog. There are two fields in the "Add Groovy" dialog: 
one for the name to give the facet, and the other is for the Groovy code. 
Identifiers may be converted to a specific format (i.e. for custom webservices) 
before being processed by the Groovy script; this is specified in the “Manage 
Dataservices” dialog and the default setting is to perform no conversion The 
Groovy script will be run once for each diagram node with an identifier and 
expects a return string or an array of strings to be displayed as facet entries. The 
online documentation goes into detail on how to use the Groovy scripting 
features and provides two in-depth examples of its use. The first example 
illustrates how users may connect histone binding data to diagram nodes by 
using Enseml BioMart to produce a facet. The second example demonstrates 
using custom web-services in the retrieval of compounds with high binding 
affinities to diagram nodes from ChEMBL (Gaulton, Bellis et al. 2012). 
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3.3.3 Conclusion  
The PathVisio-Faceted Search plugin was designed to help users better 
understand complex pathways by making it easier to cross-reference diagrams 
with data from multiple sources, both local experimental data and via 
webservices. Faceted search is a widely used search method that overcomes the 
limitations of more conventional methods to easily find relevant items. In the 
future, we plan to extend this plugin by introducing a visual programming 
interface to simplify the Groovy scripting component of the plugin and make the 
power and flexibility of this scripting support accessible to a larger segment of the 
community. 
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4 SIRT1/PARP1 CROSSTALK: CONNECTING DNA DAMAGE 
AND METABOLISM 
4.1 Introduction 
SIRT1 and PARP1 are enzymes that affect two key post-translational 
modifications: acetylation and ADP-ribosylation, respectively, for a diverse group 
of proteins. These enzymes are functionally connected due to their use of a 
common substrate, nicotinamide adenine dinucleotide (NAD+) (D'Amours, 
Desnoyers et al. 1999; Blander and Guarente 2004). Recent studies suggest that 
these proteins participate in common pathways providing cells with a mechanism 
for balancing cell survival and death. A well-developed understanding of activity 
overlap of these proteins may provide insights into the biology of these two 
proteins as they are actively being pursued as therapeutic targets in a range of 
conditions, including cancer and metabolic disorders (Rouleau, Patel et al. 2010; 
Villalba, de Cabo et al. 2012; Canto, Sauve et al. 2013).  
 
In this review, we look at the role of each of these two proteins using a Molecular 
Interaction Map (MIM) that visually integrates the experimental findings of the 
regulatory pathways that surround these proteins, shown in Figure 12. The MIM 
helps free readers from a linear view of events and gain a better understanding 
of control loops involved in these pathways (Luna, Karac et al. 2011). A machine-
readable version of the MIM is provided and viewable using PathVisio-MIM 
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(Luna, Sunshine et al. 2011). Additionally, the MIM covers in greater detail the 
interactions surrounding SIRT1 and PARP1; a complete list of annotations is also 
provided in Appendix B.  
 
Figure 13 shows a modular overview of how the SIRT1 and PARP1 interactions 
are laid out (an arrow indicates that a molecule or process from the source 
module has an interaction with a molecule or process in the target module) and 
Figure 14 provides a legend for reading the MIM notation. Throughout this review 
readers will see annotation labels in double square brackets that refer to specific 
interactions in the MIM shown in Figure 12. We focus on aspects that alter the 
activity of these proteins, including: post-translational modifications, co-
regulation, NAD+ competition and co-regulated targets. Additionally, we discuss 
outstanding questions that would more accurately describe the relationship 
between these proteins.  
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Figure 12: SIRT1 and PARP1 Molecular Interaction Map. Blue: Post-translational 
modifications, Red: Inhibition and cleavage, Green: Stimulation and catalysis, Magenta: 
Transcription and translation events. 
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Figure 13: Modular layout diagram of SIRT1 and PARP1 MIM. Arrows connecting 
modules indicate that a node starting in a module connects to a node in the target 
module.  
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Figure 14: Reference guide for the MIM notation. 
 
66 
 
 
4.2 Overview of SIRT1 and PARP1 
4.2.1 SIRT1  
Sirtuins were originally discovered in yeast where the SIR (Silent Information 
Regulator) genes are necessary for the repression of silent mating-type loci 
(Blander and Guarente 2004). SIRT1 (EC 3.5.1.-), an ortholog of Sir2, is a 
member of the sirtuin family that is expressed in many tissues and acts as a 
NAD+-dependent histone deacetylase (Blander and Guarente 2004). SIRT1 has 
been implicated in signaling pathways underlying various diseases, including: 
diabetes, cardiovascular disease, neurodegeneration, cancer, aging, and obesity 
(Rahman and Islam 2011).  
 
4.2.2 PARP1  
PARP1 (EC 2.4.2.30) is an NAD+-dependent nuclear ADP-ribosyltransferase 
with three domains: a DNA binding domain (DBD), an auto-modification domain 
(AD), and a catalytic domain [[A1]] (Mendoza-Alvarez and Alvarez-Gonzalez 
1993). The PARP family of proteins are involved in many processes, including: 
DNA damage response, cell death, cell cycle regulation, and telomere regulation 
(Ame, Spenlehauer et al. 2004). The main function of PARP1 is the formation of 
poly(ADP-ribose) (PAR) chains on itself and other proteins [[A2]] (D'Amours, 
Desnoyers et al. 1999; Hassa, Haenni et al. 2006; Messner, Altmeyer et al. 
2010). PARP1 is a transcriptional co-activator where PAR acts as a signal 
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helping to regulate transcription (Luo and Kraus 2012). PAR is quickly cleaved by 
poly (ADP-ribose) glycohydrolase (PARG) [[A3]] (Hassa, Haenni et al. 2006). 
PARP1 becomes highly activated by DNA strand breaks; electrostatic repulsion 
between the poly (ADP)-ribose (PAR) chains and DNA eventually leads to its 
catalytic inactivation (Mendoza-Alvarez and Alvarez-Gonzalez 1993).  
 
4.3 Post-transcriptional Regulation of SIRT1 and PARP1 
Phosphorylation, methylation, sumolyation, nitrosylation, acetylation, and 
ubiquitination are all modification types that affect both the catalytic activity and 
the ability of these two proteins to interact with other proteins. 
 
4.3.1 SIRT1 
For a comprehensive review of sirtuin modifications, see Flick and Luscher (Flick 
and Lüscher 2012). Below we describe several of these modifications for SIRT1 
and augment this list with additional modifications.  
 
SIRT1 phosphorylation results in both stimulatory and inhibitory effects. 
Phosphorylation of SIRT1 by JNK at S27, S47, and T530 (Nasrin, Kaushik et al. 
2009) and CK2 at S659 [[A4]] (Kang, Jung et al. 2009; Zschoernig and 
Mahlknecht 2009) helps to stimulate its deacetylation activity, while 
phosphorylation at S47 by mTOR results in the inhibition of SIRT1 [[A5]] (Back, 
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Rezvani et al. 2011). Cyclin B/Cdk1, a cell cycle-dependent kinase, can 
phosphorylate SIRT1 at T530 and S540 [[A6]]. Phosphorylation at these two sites 
decreases the activity of SIRT1 and disrupts progress of the cell cycle (Sasaki, 
Maier et al. 2008). Given that phosphorylations at S47 and T530 have been 
shown to help increase and decrease SIRT1 activity, respectively, this suggests 
that a multi-site phosphorylation regulatory mechanism is in place and may be 
involved in the regulation of the timing of SIRT1 activity (Salazar, Brummer et al. 
2010).  
 
Kinases DYRK1A and DYRK3 have been shown to phosphorylate SIRT1 at 
T522, stimulating the deacetylation of p53 by SIRT1 [[A7]] (Guo, Williams et al. 
2010). AMPK phosphorylates SIRT1 at T344 inhibiting the ability to deacetylate 
p53, a known target of SIRT1 [[A8]] (Lee, Wong et al. 2012). In addition to 
phosphorylation, methylation of SIRT1 by Set7/9 at K233, K235, K236, and K238 
inhibits the SIRT1-mediated deacetylation of p53 [[A9]] (Liu, Wang et al. 2011). 
Sumolyation at K734 by SUMO1 increases, whereas desumolyation by SENP1 
decreases, the activity of SIRT1 in response to genotoxic stress [[A10]] (Yang, 
Fu et al. 2007). Additionally, transnitrosylation of SIRT1 by GAPDH at C387 and 
C390 has been suggested to inhibit the activity of SIRT1 [[A11]] (Kornberg, Sen 
et al. 2010).  
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4.3.2 PARP1 
The activity of PARP1 can be modulated via post-translational modifications, 
including phosphorylation, sumolyation, and acetylation. DNA-PK phosphorylates 
PARP1 though its effect is unknown [[A12]] (Ruscetti, Lehnert et al. 1998). 
Phosphorylation of PARP1 by AMPK and ERK1/2 has been shown to enhance 
its activity [[A13]] (Kauppinen, Chan et al. 2006; Walker, Jijon et al. 2006). 
PARP1 is acetylated by p300/CBP; this acetylation is involved in the activation of 
NF-κB by PARP1 [[A14]] (Hassa, Haenni et al. 2005). PARP1 is sumolyated by 
SUMO1 and SUMO3 at K486 of PARP1's auto-modification domain. This 
modification inhibits the ability of p300 to acetylate PARP1 and inhibits the 
expression of genes that are transcriptionally targeted by PARP1 [[A15]] 
(Messner, Schuermann et al. 2009). 
 
4.4 Co-regulation of SIRT1 and PARP1 
4.4.1 Cross-modification and Transcriptional Co-regulation 
SIRT1 and PARP1 are transcriptionally and functionally interconnected (Zhang 
2003; Pillai, Isbatan et al. 2005; Kolthur-seetharam, Dantzer et al. 2006). In 
SIRT1-deficient mouse cardiomyocytes, Rajamohan et al. in 2009 found 
increased levels of PARP1 acetylation in response to mechanical stress, 
suggesting that SIRT1 can deacetylate PARP1 [[A16]] (Rajamohan, Pillai et al. 
2009). Whether this interaction occurs during genotoxic stress or other types of 
70 
 
 
stresses remains an open question. No similar modification reaction has been 
seen on SIRT1 by PARP1 in response to DNA damage. However, SIRT1 is able 
to negatively regulate the PARP1 promoter, and the SIRT1 promoter has been 
shown to be under the influence of PARP2 (Bai, Canto et al. 2011; Bai, Canto et 
al. 2011). 
 
4.4.2 NAD+ Competition 
Another key co-regulatory mechanism between these two proteins is the 
utilization of nicotinamide adenine dinucleotide (NAD+). It has been suggested by 
several studies that activation of PARP1 causes a depletion in NAD+ levels, 
which inhibits SIRT1 activity (Pillai, Isbatan et al. 2005; Kolthur-seetharam, 
Dantzer et al. 2006; Rajamohan, Pillai et al. 2009; Bai, Canto et al. 2011). NAD+ 
is mainly salvaged in mammals, and nicotinamide (NAM) is the major precursor 
in this process. The rate-limiting protein in the NAM-NMN-NAD+ conversion is 
nicotinamide phosphoribosyltransferase (NAMPT) [[A17]]. PARP1 was shown to 
have a greater effect on NAD+ depletion than SIRT1 in response to the NAMPT 
inhibitor, FK866 (Pittelli, Formentini et al. 2010). In a related study, the inhibition 
of NAMPT by FK866 was shown to produce an effect similar to SIRT1 depletion 
(Nakahata, Sahar et al. 2009).  
 
Recent evidence suggests that local supplies of NAD+ may be important for the 
enzymatic activities of these two proteins, shown in Figure 15 (Araki, Sasaki et 
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al. 2004; Zhang, Sang et al. 2010; Zhang, Berrocal et al. 2012). NMNAT1, 
involved in the salvage of NAD+, can bind to (ADP-ribose) polymers in vitro 
leading to the stimulation of PARP1 activity; this effect is diminished when 
NMNAT1 is phosphorylated at S136 by protein kinase c (PKC) [[A18]] (Berger, 
Lau et al. 2007). A similar interaction has been shown to occur with SIRT1, 
whereby SIRT1 binds to NMNAT1 helping to recruit NMNAT1 to specific 
promoters, which may help stimulate SIRT1 activity [[A19]] (Zhang, Berrocal et 
al. 2009). PARP1 activity leads to increased NAM concentrations at DNA 
damage sites, potentially leading to local inhibition of SIRT1 histone deacetylase 
activity (Kruszewski and Szumiel 2005). Further work is needed to understand 
the function of these two proteins around chromatin sites occupied beforehand 
by one of them.  
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Figure 15: The effect of NMNAT1 binding on SIRT1 and PARP1 activity. Zhang et al. 
proposed that NMNAT1 may stimulate SIRT1 activity; indicated by the dashed line.  
 
4.5 Regulation of Common SIRT1 and PARP1 Targets 
4.5.1 SIRT1/PARP1 Response to DNA damage 
Maintaining genomic integrity is a major activity carried out by cells. DNA 
damage response to both endogenous and exogenous sources is an intricate 
process that is not fully understood due to the complexity of the potential lesions, 
the number of proteins involved in both surveillance and repair, the 
interconnected regulation of proteins involved in the detection and repair of 
damage, stoppage of the cell cycle, and the potential induction of cell death 
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(Harper and Elledge 2007). SIRT1 and PARP1 play several roles throughout the 
response to DNA damage from the initial response to final cell fate decisions. 
 
4.5.2 Histones 
Both SIRT1 and PARP1 are known to modify histones; deacetylation of histones 
triggers chromatin compaction and the inhibition of transcription, whereas poly 
(ADP-ribose) polymers help to relax chromatin. SIRT1 is capable of deacetylating 
several histone amino acid residues, including H1K26, H3K9, H3K14, and H4K16 
[[A20]] (Imai, Armstrong et al. 2000; Vaquero, Scher et al. 2004), while PARP1 
can modify histones H1, H2AK13, H2BK30, H3K27, H3K37, and H4K16 to 
possibly regulate transcription [[A21]] (Krishnakumar and Kraus 2010; Messner, 
Altmeyer et al. 2010). It has been suggested that ADP-ribosylation of H1 
promotes transcription by inhibiting the ability of H1 to bind to DNA 
(Krishnakumar, Gamble et al. 2008). Additionally, a competitive interaction has 
been shown between acetylation and PAR where acetylation of H4K16 inhibits 
the ADP-ribosylation of histone H4 [[A22]] (Messner, Altmeyer et al. 2010). Here 
a potential contradiction in the role of SIRT1 in condensing chromatin arises 
whereby SIRT1 deacetylation activity could potentially help drive the PARP1 
ADP-ribosylation activity on H4K16. Further studies are needed to understand 
how DNA damage might affect these various histone modifications. Currently, it 
is known that genotoxic stress causes a random redistribution of SIRT1 across 
the genome with a correlated increase in levels of H1K26 acetylation 
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(Oberdoerffer, Michan et al. 2008). However, while PARP1 does localize to DNA 
strand breaks, it is also not known whether there is any further global 
redistribution PARP1 or a relationship to the redistribution of SIRT1. 
 
4.5.3 DNA Damage Signaling Pathway 
Both SIRT1 and PARP1 are DNA damage responders and the absence of either 
of these proteins may lead to DNA damage sensitization (Matsushita, Takami et 
al. 2005; Aguilar-Quesada, Munoz-Gamez et al. 2007). PARP1 begins to localize 
to DNA breaks rapidly after activation, and its ADP-ribosylation activity increases 
10-500 fold as a result of binding to DNA breaks [[A23]] (D'Amours, Desnoyers et 
al. 1999). Once activated, PARP1 may help repair single strand DNA breaks, 
preventing their conversion to double-stranded breaks (DSB) [[A24]] 
(Woodhouse, Dianova et al. 2008). In addition, PARP1 is involved in DNA repair 
through its associations with base excision repair (BER) enzymes such as 
polymerase β, XRCC1 and DNA ligase III by helping these proteins localize to 
sites of DNA damage [[A25]] (de Murcia, Niedergang et al. 1997). 
 
Two early responders of DNA damage linked to SIRT1 and PARP1 regulation 
are ATM (ataxia telangiectasia, mutated) and CHK2 (checkpoint kinase 2) 
(Gorospe and de Cabo 2008). The activation of ATM by DNA breaks requires the 
activation of the MRE11-RAD50-NBS1 (MRN) complex [[A26-A28]]. It has been 
shown that PARP1 binds to ATM, an interaction that is stimulated by DNA 
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damage, and that the automodification of PARP1 leads to ATM activation [[A29]] 
(Aguilar-Quesada, Munoz-Gamez et al. 2007).  
 
An extended feedback loop has been proposed by Gorospe and de Cabo 
involving SIRT1 and several key DNA damage repair proteins (Gorospe and de 
Cabo 2008). In this loop, NBS1 is phosphorylated by ATM at S343 for the 
activation of NBS1; to be phosphorylated, it is necessary for NBS1 to be in a 
hypoacetylated state, which SIRT1 helps to maintain by deacetylating NBS1 
[[A30-A31]] (Yuan and Seto 2007). CHK2 is activated when T68 is 
phosphorylated by ATM. CHK2 can then phosphorylate HuR at several sites 
causing it to dissociate from SIRT1 mRNA, and thereby reduce the half-life of the 
SIRT1 mRNA [[A32]] (Abdelmohsen, Pullmann et al. 2007). It has been 
suggested that in repairable DNA damage situations SIRT1 levels are elevated 
leading to a survival response, but during lethal DNA damage SIRT1 levels can 
be attenuated by CHK2 through the phosphorylation of HuR that ultimately 
results in cell death (Gorospe and de Cabo 2008).  
 
SIRT1 is also regulated by c-MYC and E2F1, two proteins involved in cell 
proliferation, differentiation and apoptosis, through negative feedback loops 
shown in Figure 16. E2F1, a transcription factor, induces the transcription of 
SIRT1 [[A33]]. Conversely, E2F1 has been suggested to be a target for SIRT1 
deacetylation, which inhibits E2F1 activity [[A34-A35]] (Wang, Chen et al. 2006). 
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Two studies have examined the interactions between SIRT1 and c-MYC 
producing contradictory results. In one publication, c-MYC over-expression leads 
to an increase in SIRT1 expression and then deacetylation of c-MYC by SIRT1 
leads to the destabilization of c-MYC [[A36]] (Yuan, Minter-Dykhouse et al. 
2009). In the second publication, neither the induction of SIRT1 expression nor 
the destabilization of c-MYC was seen following c-MYC activation. Instead, a 
stabilizing effect on c-MYC due to deacetylation by SIRT1 was found. Also, 
Menssen et al. found that c-MYC can induce the transcription of NAMPT and 
help sequester DBC1, an inhibitor of SIRT1 [[A37]] (Menssen, Hydbring et al. 
2012). Another line of evidence suggesting that SIRT1 may affect NAMPT 
through a second mechanism involving the circadian clock will be discussed 
later. There is evidence that PARP1 binds to E2F1 stimulating E2F1-dependent 
transcription of c-MYC [[A38]] (Simbulan-Rosenthal, Rosenthal et al. 2003). This 
presents the possibility that both SIRT1 and PARP1 may be capable of 
influencing the regulation of NAMPT to affect NAD+ levels through c-MYC.  
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Figure 16: Interactions between SIRT1 and transcription factors c-MYC and E2F1. 
Solid lines between SIRT1 and c-MYC indicated are interactions from Yuan, Minter-
Dykhouse et al. 2009 forming a negative feedback loop, while dashed lines are findings 
related to SIRT1 and c-MYC from Menssen, Hydbring et al. 2012. 
 
Another co-regulated protein is NF-κB, a regulator of cellular response, including 
inflammation, to stress. In the case of NF-κB the effects of SIRT1 and PARP1 
are opposing. SIRT1 can deacetylate the RelA/p65 subunit of NF-κB at K310 to 
inhibit NF-κB transactivation activity [[A39]] (Yeung, Hoberg et al. 2004). PARP1 
is an activator of NF-κB through its direct binding to NF-κB; acetylation of PARP1 
by p300/CBP is required for the binding of PARP1 to NF-κB [[A40]] (Hassa, 
Haenni et al. 2005). 
 
Given the importance of p53 to apoptotic response, a number of studies have 
focused on the regulation of p53 by SIRT1. p53 acts as a transcription factor that 
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induces apoptosis and is inhibited by SIRT1 deacetylation [[A41]] (Liang, Finkel 
et al. 2008; Levine and Oren 2009). SIRT1 has the capability of deacetylating 
p53 at several sites in mouse embryonic fibroblasts (MEFs) and SIRT1-deficient 
cells possess hyperacetylated p53 [[A42]] (Luo, Nikolaev et al. 2001; Brooks and 
Gu 2009). Several proteins help to modify the interactions of SIRT1 with p53, 
including p53 (itself), DBC1, AROS, and HIC1, suggesting that it is a cellular 
imperative to control the inhibition of p53 by SIRT1 under certain conditions. p53 
can repress SIRT1 expression during nutrient abundance via p53-binding sites 
on the SIRT1 promoter. This effect is countered by the transcription factor 
FOXO3A, which interacts with p53 in an inhibitory fashion during nutrient 
deprivation [[A43-A44]] (Nemoto, Fergusson et al. 2004; Shang, Zhou et al. 
2009). Hypermethylated in cancer-1 (HIC1) is a transcriptional repressor of the 
SIRT1 promoter [[A45]] that helps prevent age-dependent cancers in mice. If 
HIC1 is inhibited, SIRT1 expression increases, allowing for more efficient 
inactivation of p53; p53 over-expression leads to the transactivation of HIC1, thus 
creating a negative feedback loop (Chen, Wang et al. 2005). Micro-RNAs have 
also been shown to downregulate SIRT1-dependent deacetylation of p53. p53 
can stimulate the expression of miRNA-34 [[A46]], which subsequently drives 
down the expression of SIRT1 lowering SIRT1 availability to inhibit p53; over 15 
micro-RNAs affect the expression of SIRT1 either directly or by decreasing the 
expression of HuR, which stabilizes SIRT1 mRNA [[A47]] (Yamakuchi and 
Lowenstein 2009; Yamakuchi 2012). 
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Given the well-studied nature of p53 as a SIRT1 substrate, p53 has been used to 
characterize SIRT1 inhibitors and activators. In humans, deleted in breast cancer 
1 (DBC1) acts as an inhibitor of SIRT1 (an inhibitory effect increased by the 
phosphorylation of DBC1) and whose effect has been shown to lead to p53 
hypoacetylation [[A48-A49]] (Kim, Chen et al. 2008; Zhao, Kruse et al. 2008; 
Kang, Suh et al. 2011; Yuan, Luo et al. 2012). Active Regulator of SIRT1 (AROS) 
has been shown to bind SIRT1 and help enhance the deacetylation of p53 by 
SIRT1 [[A50]] (Kim, Kho et al. 2007). Further studies are needed to understand if 
the effects on p53 acetylation states are specific to the activities of DBC1 and 
AROS on SIRT1 or if other substrates of these two proteins are involved.  
 
Much less is known about the interaction between PARP1 and p53. PARP1 
helps p53 accumulate in the nucleus by (ADP-ribosyl)ating p53, which prevents 
p53 nuclear export (Kanai, Hanashiro et al. 2007). There is evidence to suggest 
that SIRT1 deacetylation activity is capable of blocking p53 nuclear translocation 
(Han, Song et al. 2008).  
 
4.5.4 Cell Death 
Both SIRT1 and PARP1 play a role in determining cell fate in response to 
genotoxic stress. In addition to the role that SIRT1 plays in the inhibition of p53, 
SIRT1 is capable of deacetylating Ku70 at K539 and K542; the acetylation of 
Ku70 leads to the dissociation of the Ku70 and Bax helping to trigger apoptosis; 
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Bax is a pro-apoptotic factor that is sequestered by Ku70 [[A51-A52]] (Cohen, 
Miller et al. 2004). NBS1, deacetylated by SIRT1, helps control the interaction 
between Ku70 and Bax by stimulating the acetylation of Ku70 [[A53]] (Iijima, 
Muranaka et al. 2008).  
 
PARP1 plays a role in cell death pathways (apoptosis or necrosis) in the course 
of responding to DNA damage. Apoptosis is programmed cell death that that 
utilizes energy, while necrosis is initiated upon energy loss. During normal 
apoptosis, PARP1 is cleaved by caspases; the role that these cleaved fragments 
play is not fully understood [[A54]]. PARP1 cleavage helps prevent energy 
depletion (NAD+ and ATP) in response to severe DNA damage; the extreme loss 
of NAD+ triggers necrosis by reducing cellular ability to synthesize ATP [[A55]] 
(Koh, Dawson et al. 2005). Cells with severe DNA damage die from necrosis 
because they are not able to switch away from the necrotic pathway since the 
kinetics of NAD+ depletion are faster than those of PARP1 cleavage (D'Amours, 
Desnoyers et al. 1999). PARP1 has also been implicated in caspase-
independent apoptosis, where its activation leads to apoptosis-inducing factor 
(AIF) release from the mitochondria, which induces nuclear chromatin 
fragmentation [[A56]] (Wang, Kim et al. 2011). 
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4.6 Circadian Rhythms  
Recent SIRT1 and PARP1 research has uncovered roles for the two proteins in 
circadian rhythms creating the possibility for novel interconnections between 
metabolism, DNA repair, and circadian rhythms (Figure 17). The core circadian 
machinery involves a transactivating CLOCK/BMAL1 heterodimer, which induces 
the transcription of a large number of genes, including the cryptochrome (CRY1 
and CRY2) and period (PER1, PER2, PER3) genes that form a complex that 
leads to a negative feedback loop suppressing CLOCK/BMAL1-mediated 
transcription [[A57-A59]]. Several studies have shown that disruptions in core 
circadian interactions can lead to alterations in DDR; previously reviewed (Rana 
and Mahmood 2010).  
 
SIRT1 deacetylates BMAL1 at K537 destabilizing the interaction between CRY 
and BMAL1 [[A60]] (Hirayama, Sahar et al. 2007; Nakahata, Kaluzova et al. 
2008). CLOCK possesses acetyltransferase activity that regulates the 
transcriptional activity of CLOCK/BMAL1 (Doi, Hirayama et al. 2006) and is 
capable of acetylating some of the same locations that SIRT1 deacetylates: 
H3K9, H3K14, and BMAL1 at K537 [[A61]] (Imai, Armstrong et al. 2000; 
Nakahata, Kaluzova et al. 2008). SIRT1 has also been shown to deacetylate 
PER2 destabilizing the protein [[A62]]; it has been hypothesized that acetylation 
of PER2 at lysine residues prevents their ubiquitination (Asher, Gatfield et al. 
2008). This presents a dual control mechanism for SIRT1 in the circadian clock 
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where it is capable of balancing transcription through chromatin condensation, 
but also by disrupting the ability for CRY and PER2 to repress CLOCK/BMAL1 
activity. SIRT1 is involved in NAMPT transcriptional regulation, which is under 
circadian control causing NAD+ levels to oscillate (Nakahata, Sahar et al. 2009; 
Ramsey, Yoshino et al. 2009). Additionally, it has been shown that PARP1 has 
rhythmic activity influenced by feeding patterns though further work is necessary 
to understand the underlying molecular mechanism. PARP1 is also capable of 
ADP-ribosylating CLOCK in a circadian manner disrupting the association 
between the BMAL1/CLOCK heterodimer and its targets [[A63]] (Asher, Reinke 
et al. 2010). It remains to be determined whether a regulatory effect exists 
between SIRT1 or PARP1 and the circadian components during DNA damage. 
 
 
Figure 17: Interactions of SIRT1 and PARP1 with circadian clock components. 
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4.7 Concluding Remarks  
Cells respond to DNA damage through coordinated pathways that arrest the cell 
cycle and repair the damage, and in the presence of severe damage trigger cell 
death. Both SIRT1 and PARP1 play an intimate role in the regulation of genomic 
stability, and continued work is necessary for the understanding of the specific 
contexts in which modulators of SIRT1 and PARP1 activity may be appropriate 
as therapeutics for cancer and metabolic disorders. The regulation of SIRT1 and 
PARP1 is controlled by a variety of stimuli, including metabolic, circadian, and 
genotoxic. Understanding how each of these stimuli affects the regulatory 
network of these two proteins is vital. 
 
The work of the past several years has trended towards an understanding of the 
diverse regulatory network surrounding these two proteins, the effects of local 
levels of their common substrate, NAD+, and the co-regulation of and by the two 
proteins. There continue to be several unexplored areas. For example, 
understanding the nature of competitive regulation of acetylation and PAR at a 
single substrate residue on a single molecule, since both can target lysine 
residues, remains an open area of research. Another interesting avenue of 
research remaining to be thoroughly explored is the alteration of the reviewed 
pathways as an organism ages. Studies have shown age-dependent increases in 
DNA damage can lead to NAD+ depletion (Braidy, Guillemin et al. 2011; 
Massudi, Grant et al. 2012). In human tissue samples, Massudi et al. found an 
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age-related positive correlation in PARP1 activity in males and negative 
correlations with SIRT1 activity in males and NAD+ levels in both males and 
females that starts to shed light on the role of these two proteins in the presence 
of accumulating DNA damage with age (Massudi, Grant et al. 2012). Additionally, 
there is a deficit in our knowledge with respect to the influence that DNA damage 
response may have on circadian regulation and vice versa and the roles that 
SIRT1 and PARP1 may play. And while this review focuses on evidence of the 
interactions between the better studied members of their respective protein 
families, SIRT1 and PARP1, additional work is necessary in our understanding of 
the roles of the other members of the two protein families and their unique 
properties and interactions that may play integral roles in the progression of 
DDR, as well as other processes. For instance, it is known that SIRT6, another of 
the nuclear sirtuins, has a role in promoting DNA damage repair by binding and 
activating PARP1 by mono-ADP-ribosylating PARP1, thereby triggering its auto-
ADP-ribosylation activity [[A64]] (Mao, Hine et al. 2011). 
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5 PREDICTED ROLE OF NAD+ UTILIZATION IN THE 
CONTROL OF CIRCADIAN RHYTHMS DURING DNA DAMAGE 
RESPONSE 
5.1 Introduction 
Circadian rhythms are biological oscillations occurring with an approximately 24 
hour period affecting many processes. In mammals, these oscillations are 
centrally controlled in the brain by the suprachiasmatic nuclei (SCN). The SCN 
synchronizes the peripheral circadian clocks that exist in nearly every cell. 
Disruption of the circadian clock can lead to higher incidence of certain forms of 
cancer, and circadian timing can affect both the tolerability and efficacy of cancer 
therapeutics though the underlying mechanisms for these effects are still not 
well-understood (Levi, Okyar et al. 2010; Leonardi, Rapisarda et al. 2012). There 
is evidence that mutations of core circadian components in tumors can affect 
several properties of circadian oscillations, including: changes in amplitude, 
phase shifts, and period (Mormont and Levi 1997).  
 
Investigation into the molecular components of the circadian clock has revealed 
much about how these biological rhythms function. In mammals, the core of the 
circadian clock is coordinated by four components that operate in a transcription-
translational feedback loop. The positive arm of the circadian clock involves a 
  
86 
transactivating heterodimer complex composed of Brain and Muscle Arnt-Like 
protein-1 (BMAL1) and Circadian Locomotor Output Cycles Kaput (CLOCK) that 
induces the transcription of many genes; the current model and its simplifications 
are described in the Model section. Gene expression microarray analyses have 
shown that as much as 10% of an organism's transcriptome could be under 
circadian influence with expression exhibiting circadian oscillations; this value is 
dependent on experimental conditions and the tissue of origin (Ptitsyn and 
Gimble 2011). The BMAL1/CLOCK transactivating complex operates on E-box 
regions of gene promoters. Additionally, CLOCK is an acetyltransferase involved 
in chromatin remodeling; a function necessary to the proper operation of the 
circadian clock mechanism (Doi, Hirayama et al. 2006). The negative arm of the 
circadian clock involves the Cryptochrome (CRY1 and CRY2) and Period (PER1, 
PER2, and PER3) genes that act as inhibitors of the BMAL1/CLOCK 
transcription factor complex. CRY/PER heterodimers in the nucleus suppress 
CLOCK/BMAL1-mediated transcription completing the feedback loop, which then 
repeats as the levels of CRY/PER complex diminish (Reppert and Weaver 2001). 
The degradation of CRY/PER levels is partially triggered by phosphorylation, 
which marks the PER proteins for proteasomal degradation (Eide, Woolf et al. 
2005). This phosphorylation of the PER occurs via CKI-epsilon (Casein Kinase I-
epsilon). There is also evidence that period (PER) proteins have been shown to 
interact with ATM and CHK2, two key proteins involved in DNA damage 
response; the Neurospora ortholog for CHK2, PRD-4, has been shown to 
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promote the phosphorylation of the PER protein analogue in Neurospora, FRQ 
(Gery, Komatsu et al. 2006; Pregueiro, Liu et al. 2006). 
 
Several studies show the existence of interplay between the pathways regulating 
circadian rhythms and those regulating DNA damage response. For example, 
disruptions to the core components can lead to alterations in DNA damage 
response pathways through altered expression patterns (Rana and Mahmood 
2010). The reverse has also been shown to be the case, in that circadian 
oscillations can be reset by genotoxic stress (Oklejewicz, Destici et al. 2008; 
Engelen, Janssens et al. 2013). In Oklejewicz et al., Rat-1 fibroblasts were 
subjected to pulses of ionizing radiation resulting primarily in phase 
advancements of circadian oscillations (Oklejewicz, Destici et al. 2008). Other 
forms of perturbation produce phase advancements and delays, such as in the 
case of pharmacological perturbation with dexamethasone (Izumo, Sato et al. 
2006). Dexamethasone is a glucocorticoid agonist capable of resetting the 
circadian phase of asynchronous cells by triggering the expression of PER1 
(Reddy, Maywood et al. 2007). 
 
The molecular basis for the regulation of the circadian clock in the presence of 
genotoxic stress continues to be explored (Oklejewicz, Destici et al. 2008; 
Engelen, Janssens et al. 2013). As our understanding of circadian regulation 
expands, so do the interconnections with other biological processes. Several 
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recent studies have shown the circadian clock to be regulated by proteins, such 
as SIRT1, involved with DNA damage response and cellular metabolic state 
through their consumption of nicotinamide adenine dinucleotide (NAD+) 
(Nakahata, Kaluzova et al. 2008; Nakahata, Sahar et al. 2009). NAD+ is a well-
known metabolite that participates in many oxidation-reduction reactions and 
functions, including ATP production (Rongvaux, Andris et al. 2003). Supplies of 
NAD+ are under circadian regulation due to circadian oscillation of nicotinamide 
phosphoribosyltransferase (NAMPT) that controls a rate-limiting step in the 
salvage of NAD+ (Nakahata, Sahar et al. 2009; Ramsey, Yoshino et al. 2009).  
 
In its DNA damage response role, NAD+ is involved in cell fate decisions through 
its utilization by PARP1 and SIRT1. PARP1 is an ADP-ribosyltransferase where 
the ADP-ribosyl moieties are obtained from the cleavage of NAD+. PARP1 is 
activated in the presence of DNA strand breaks (its activity can increase 10-500 
fold) and helps to recruit DNA repair proteins (de Murcia, Niedergang et al. 1997; 
D'Amours, Desnoyers et al. 1999). At severe levels of DNA damage, energy 
depletion due to loss of NAD+ and ATP may trigger necrosis rather than 
apoptosis (D'Amours, Desnoyers et al. 1999; Koh, Dawson et al. 2005).  
 
SIRT1 is an NAD+-dependent protein deacetylase that can help regulate 
transcription through histone deacetylation. The acetylation of histones leads to 
the activation of gene expression by inducing a relaxed chromatin confirmation at 
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gene promoters, which permits the access of DNA transcription proteins 
(Nakahata, Kaluzova et al. 2008). Histone acetylation is counter-balanced 
through deacetylation causing a condensed chromatin state and transcriptional 
silencing. SIRT1 is involved in DNA damage response through interaction with 
several key proteins, such as p53, where the deacetylation of p53 inhibits p53 
and promotes cell survival (Kwon and Ott 2008). More recently, SIRT1 has been 
implicated in the regulation of the circadian clock in several ways. First, SIRT1 
destabilizes the interaction between CRY and BMAL1 through the deacetylation 
of BMAL1; the deacetylation of BMAL1 is counter-balanced at the same position 
through the acetyltransferase activity of CLOCK (Hirayama, Sahar et al. 2007; 
Nakahata, Kaluzova et al. 2008). Second, SIRT1 has been shown to deacetylate 
PER destabilizing the protein and promoting its degradation (Asher, Gatfield et 
al. 2008). Finally, SIRT1 is recruited to promoters of PER2 and NAMPT and is 
involved in the chromatin remodeling of the vicinity of each of the two promoters 
(Nakahata, Sahar et al. 2009).  
 
The circadian clock has been the subject of several mathematical models that 
have helped in our understanding of the molecular mechanisms underlying 
regulation of the circadian clock (Gonze, Halloy et al. 2002; Gallego, Eide et al. 
2006). Our understanding of the NAD+ circadian regulation dynamics and the 
molecular mechanism regulating the phase resetting response of the circadian 
clock upon exposure to genotoxic stress remains incomplete; given the 
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interactions mentioned above, there is the possibility that NAD+ utilization may 
be involved. We have developed an ordinary differential equation (ODE) model 
that includes the role of NAD+ in the regulation of SIRT1. The current study 
explores the potential role of NAD+ depletion in phase resetting of the circadian 
clock through the activities of the NAD+ consumers, SIRT1 and PARP1. Our 
study explores the dynamics of NAD+ depletion on the circadian rhythms. Also, 
we examine the effect of multiple perturbations on the circadian cycle and how 
these multiple perturbations may account for this observed behavior of the 
primarily phase advancement phase resetting response seen during DNA 
damage perturbations of the circadian clock.  
5.2 Methods  
5.2.1 Model 
We have developed a simple model (referred to here as the current model) 
representing the circadian clock of mammals, which extends a previous model 
developed by Hong et al. (referred to here as the Hong 2009 model) (Hong, 
Zámborszky et al. 2009). As in the Hong 2009 model, we only consider the 
activity of the PER protein and have subsumed the paralogs of the CRY 
(Cryptochrome) and PER (Period) genes into a single species CP in order to 
simplify the model. Within the model, PER can exist as a monomer, dimer, or in 
complex with BMAL1/CLOCK. BMAL1/CLOCK is inactivated when it exists in a 
complex with the PER dimer. Each form of PER contains a phosphorylation term 
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that simulates the phosphorylation that triggers proteasomal degradation (Eide, 
Woolf et al. 2005).  
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Figure 18: Molecular Interaction Map (MIM) wiring diagram of the simulated 
system. 
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Figure 18 shows a wiring diagram for the current model using the Molecular Interaction 
Map (MIM) notation for bioregulatory networks and drawn using PathVisio-MIM (Luna, 
Karac et al. 2011; Luna, Sunshine et al. 2011). Each interaction is labelled and 
described in Table 4; these descriptions are used to label the reactions in the SBML 
model file.  
 
The original form of CRY/PER mRNA transcription in the Hong 2009 model used 
a Hill function, but this is zeroed out in the current model using kms (kms=0) in 
Equation 1 (below). We extend the Hong 2009 model to account for the effects of 
acetylation on transcription for both PER and NAMPT by using Equation 1 
through Equation 15 from Smolen et al. re-worked for the system described here 
(Smolen, Hardin et al. 2004). Deacetylation of histones results in chromatin 
compaction and decreased transcription as a result of lowered accessibility of 
DNA polymerase to these regions of condensed chromatin. In the case of PER, 
the first term of Equation 8 accounts for the fractional levels of histone 
acetylation. The rate of promoter acetylation is a function of acetylation regulated 
by the BMAL1/CLOCK (TF) complex through CLOCK acetyltransferase activity 
and inhibited by the effects PER dimer, Equation 13. Further, it is known that 
CLOCK is able to acetylate histones at positions deacetylated by SIRT1 
(Nakahata, Kaluzova et al. 2008). The rate of histone acetylation is regulated by 
the basal rate of histone deacetylation and the SIRT1 deacetylation, activity 
simulated as a two substrate Michaelis-Menten reaction that utilizes NAD+ in the 
process; the activity of SIRT1 is discussed further below. Therefore, unlike 
Smolen et al., we do not use a single, fixed deacetylation rate (Smolen, Hardin et 
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al. 2004). This is consistent with the work of Nakahata et al., which showed that 
peak SIRT1 deacetylation activity coincided with the lowest acetylation levels of 
histone H3 (Nakahata, Kaluzova et al. 2008). This level of single histone 
acetylation is then used to generate an overall promoter accessibility value, 
Equation 9. Lastly, this promoter accessibility value is multiplied by a maximal 
rate of transcription to denote the expression of PER, Equation 1. The same 
mechanism is used to denote the expression of NAMPT.     
 
Neither SIRT1 expression nor protein levels are under circadian control, yet its 
deacetylation activity is regulated in a circadian manner (Nakahata, Kaluzova et 
al. 2008). Therefore, we do not consider changes to SIRT1 levels and only 
consider the ability of SIRT1 to utilize NAD+ to deacetylate three species (PER, 
BMAL1/CLK, and acetylated histone) within the model, thereby affecting 
circadian rhythms via separate mechanisms. First, SIRT1 deacetylates PER2 
destabilizing the protein and promoting its degradation (Asher, Gatfield et al. 
2008). Second, acetylation of BMAL1 promotes the binding of CRY1 to BMAL1 
and BMAL1 is a target of SIRT1 deacetylation (Grimaldi, Nakahata et al. 2007). 
Third, as a histone deacetylase SIRT1 is able to deacetylate lysine residues of 
histones helping to produce transcriptionally silenced chromatin that exists with a 
closed chromatin structure (Blander and Guarente 2004). Two parameters 
specify the activity of SIRT1 in the model. The first parameter VSIRT1c regulates 
the deacetylation of PER (either monomer, dimer, or in complex with 
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BMAL1/CLOCK) and the second parameter, VSIRT1d, regulates the histone 
deacetylation. The levels of NAD+ production are regulated using a first-order 
reaction dependent on the availability of NAMPT. The model includes 
perturbation inputs from the Hong 2009 model, dexamethosone (Dex) and the 
CHK2 phosphorylation (kchk2 affecting PER monomer and dimer and kchk2c 
affecting PER in complex with BMAL1/CLOCK).  
 
All simulations were conducted using MATLAB (http://www.mathworks.com). 
Copies of our model are available as a Systems Biology Markup Language 
(SBML) generated using COPASI (http://www.copasi.org).   
 
5.2.2 Kinetic equations 
The model is a system of 11 equations described above and shown below. 
Equation 12 and Equation 13 denote the rate promoter acetylation for the 
NAMPT and PER promoters, respectively. Equation 14 denotes the level of 
inactive complex, while Equation 15 is the total amount of PER that exists in the 
system.   
 
Equation 1: CRY/PER mRNA 𝑑𝑀𝑑𝑡 = 𝑉𝑀 ∙ 𝑂𝑃!" − 𝑘!" ∙𝑀 + 𝐷𝑒𝑥 + 𝑘!" ∙ 𝑇𝐹!𝐽! + 𝑇𝐹!  
 
  
96 
Equation 2: BMAL1/CLOCK complex 𝑑𝑇𝐹𝑑𝑡 = −𝑘!"#𝐶𝑃2 ∙ 𝑇𝐹 + 𝑘!!𝐼𝐶𝐽! + 𝐶𝑃!"! + 𝑘!!!!! ∙ 𝐼𝐶 + 𝑘!"!!𝐼𝐶 + 𝑘!"#𝐼𝐶 − 𝑉!"#$!!𝐼𝐶 ∙ 𝑁𝐴𝐷𝑘!"#$%&'! ∙ 𝑘!"#$%&'! + 𝑘!"#$%&'! ∙ 𝐼𝐶 + 𝐼𝐶 ∙ 𝑁𝐴𝐷 
 
Equation 3: CRY/PER protein monomer 𝑑𝐶𝑃𝑑𝑡 = − 𝑉!"#$!!𝐶𝑃 ∙ 𝑁𝐴𝐷𝑘!"#$%&'! ∙ 𝑘!"#$%&'! + 𝑘!"#$%&'! ∙ 𝐶𝑃 + 𝐶𝑃 ∙ 𝑁𝐴𝐷 − 𝑘!!!!𝐶𝑃 − 𝑘!! ∙ 𝐶𝑃𝐽! + 𝐶𝑃!"! + 2𝑘!𝐶𝑃2 − 2𝑘!𝐶𝑃 ∙ 𝐶𝑃 − 𝑘!"#𝐶𝑃 + 𝑘!"#𝑀 
 
Equation 4: CRY/PER protein dimer 𝑑𝐶𝑃2𝑑𝑡 = − 𝑉!"#$!!𝐶𝑃2 ∙ 𝑁𝐴𝐷𝑘!"#$%&'! ∙ 𝑘!"#$%&'! + 𝑘!"#$%&'! ∙ 𝐶𝑃2 + 𝐶𝑃2 ∙ 𝑁𝐴𝐷 − 𝑘!"#𝐶𝑃2 ∙ 𝑇𝐹 − 𝑘!!!!𝐶𝑃2 − 𝑘!!𝐶𝑃2𝐽! + 𝐶𝑃!"! − 𝑘!"!!𝐶𝑃2 + 𝑘!"#𝐼𝐶− 𝑘!𝐶𝑃2 + 𝑘!𝐶𝑃 ∙ 𝐶𝑃 
 
Equation 5: NAMPT mRNA 𝑑𝑁𝑑𝑡 = 𝑉𝑁 ∙ 𝑂𝑃!" − 𝑘!"𝑁 
 
Equation 6: NAMPT protein  𝑑𝑁𝑃𝑑𝑡 = −𝑘!"#𝑁𝑃 + 𝑘!"#𝑁 
 
Equation 7: Single histone acetylation (NAMPT promoter) 𝑑𝐴𝐶!"𝑑𝑡 = − 𝑉!"#$!!𝐴𝐶!"𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!"#$%&'!𝐴𝐶!" + 𝐴𝐶!"𝑁𝐴𝐷 − 𝑘!!!" ∗ 1 − 𝐴𝐶!" − 𝑘!!!"#$ ∗ 𝐴𝐶!" 
 
Equation 8: Single histone acetylation (CRY/PER promoter) 𝑑𝐴𝐶!"𝑑𝑡 = − 𝑉!"#$!!𝐴𝐶!"𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!"#$%&'!𝐴𝐶!" + 𝐴𝐶!"𝑁𝐴𝐷 + 𝑘!!!" ∗ 1 − 𝐴𝐶!" − 𝑘!!!"#$ ∗ 𝐴𝐶!" 
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Equation 9: DNA Accessibility Value (CRY/PER promoter) 𝑑𝑂𝑃!"𝑑𝑡 = 𝐴𝐶!"!!" − 𝑂𝑃!"𝑇!"#$%_!"  
 
Equation 10: DNA Accessibility Value (NAMPT promoter) 𝑑𝑂𝑃!"𝑑𝑡 = 𝐴𝐶!"!!" − 𝑂𝑃!"𝑇!"#$%_!"  
 
Equation 11: NAD+ 𝑑𝑁𝐴𝐷𝑑𝑡 = − 𝑉!"#$!!𝐴𝐶!"𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!"#$%&'!𝐴𝐶!" + 𝐴𝐶!"𝑁𝐴𝐷 − 𝑉!!"#!!𝐴𝐶!"𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!"#$%&'!𝐴𝐶!" + 𝐴𝐶!"𝑁𝐴𝐷
− 𝑉!"#$!!𝐼𝐶 ∙ 𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!"#$%&'!𝐼𝐶 + 𝐼𝐶 ∙ 𝑁𝐴𝐷 − 𝑉!"#$!!𝐶𝑃2 ∙ 𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!!"#$%&!𝐶𝑃2 + 𝐶𝑃2 ∙ 𝑁𝐴𝐷− 𝑉!"#$!!𝐶𝑃 ∙ 𝑁𝐴𝐷𝑘!"#$%&'!𝑘!"#$%&'! + 𝑘!"#$%&'!𝐶𝑃 + 𝐶𝑃 ∙ 𝑁𝐴𝐷 − 𝑘!"##𝑁𝐴𝐷 + 𝑉𝑁𝐴𝐷𝑐 ∙ 𝑁𝑃 − 𝑘!"#!𝑁𝐴𝐷 
 
Equation 12: Rate of NP promoter acetylation 
𝑘!"#$ = 𝑇𝐹𝑇𝐹 + 𝐾!"#$ ∙ 𝐾!"!!"𝐾!"!!" + 𝐶𝑃2 
 
Equation 13: Rate of CP promoter acetylation 
𝑘!"#! = 𝑇𝐹𝑇𝐹 + 𝐾!"#$ ∙ 𝐾!"!!"𝐾!"!!" + 𝐶𝑃2 
 
Equation 14: Inactive complex (BMAL1/CLOCK and PER dimer) 𝐼𝐶 = 𝑇𝐹!"! − 𝑇𝐹 
 
Equation 15: Total amount of PER 𝐶𝑃!"! = 𝐶𝑃 + 2𝐶𝑃2 + 2𝐼𝐶 
 
5.2.3 Kinetic parameters 
Kinetic parameters used for the current model are described in  
  
98 
Table 1; the table also lists the parameter values necessary to reconstitute the 
Hong 2009 model. Rate constants were based on previously published circadian 
models (Smolen, Hardin et al. 2004; Hong, Zámborszky et al. 2009). Kinetic 
parameters unique to the current model were then optimized to generate 
oscillations in the current work. Rate constants are in units of h-1. The resulting 
amplitudes have similar orders of magnitude to the original Hong 2009 model. 
 
5.2.4 Initial values 
Initial values used in the current model are described in Table 2; initial values to 
reconstitute the Hong 2009 model are also listed in Table 2. The concentrations 
of proteins and metabolites are in arbitrary units (AU) because these are 
currently not known for many circadian clock proteins.  
 
5.2.5 Simulation of DNA damage response  
Damage was simulated by altering levels of kparp and kchk2 as described in the 
Results section using the parameters in Table 3.  
 
5.2.6 Period Calculation 
The period was calculated by finding the mean of the simulated results and then 
finding the time points where a selected time point was greater than the mean 
and the subsequent time point was less than the mean. For each of the selected 
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time points, the previous time point was subtracted to produce the period value. 
The resulting values were then averaged for the final period value; a requirement 
was imposed that at least seven oscillations were necessary to produce this 
value otherwise an error value was produced. The period was calculated using 
the time series for the CRY/PER (CP) protein. 
 
5.2.7 Phase Response Curve (PRC) Calculation 
Differences in phase were calculated after 19 days (19 circadian oscillations) 
between the unperturbed and perturbed systems. The phase shift (advancement 
or delay) was the calculated difference between oscillation peaks for the two 
systems. Treatments were induced at each circadian hour, and the phase 
response curve was calculated using the time series data for the CRY/PER (CP) 
protein.  
 
5.3 Results 
5.3.1 Comparison of Simulated Oscillations to Previous 
Experimental Results 
Figure 19 illustrates the oscillatory behavior simulated by the model for the core 
circadian components using the current parameter set outlined in Table 1. The 
system oscillates with an autonomous period of 23.8 hours, which is well within 
the range seen in circadian oscillations of mice (Schwartz and Zimmerman 
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1990). The current model simulates a free-running circadian clock without 
external stimuli or cues (zeitgebers) periodically synchronizing the clock and this 
is the state in which current model results are described. The model can account 
for entrainment by varying the Dex as a square-wave, increasing the value of 
Dex to 0.125 for 12 hours and decreasing it to 0 for another 12 hours (data not 
shown). Circadian models, such as the one by Leloup and Goldbeter in 2003, 
make use of varying PER transcription to simulate the effect of light entrainment. 
Dexamethasone with its ability to trigger PER transcription therefore is a suitable 
substitute for entrainment by PER (Leloup and Goldbeter 2003; Reddy, Maywood 
et al. 2007).  
 
Figure 20 illustrates the oscillations in the histone acetylation levels for both PER 
and NAMPT mRNA. Histone acetylation levels peak at approximately hour 22 in 
Figure 20, helping the relaxation of DNA to permit transcription to be initiated. 
The peak levels of PER and NAMPT mRNA are then reached after a lag of ~6 
hours. Experimentally, peaks in the acetylation levels of histones H3 and H4 
have been observed 4 and 8 hours in advance of the PER1 and PER2 mRNA 
peaks (Naruse, Oh-hashi et al. 2004). Acetylated histone and NAD+ levels 
oscillate in antiphase, as seen when comparing Figure 20 and Figure 21. This is 
a feedback mechanism involving NAD+ production and SIRT1 activity where 
NAD+ levels rise to their peak levels ~5 hours after the peak levels of NAMPT 
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mRNA production. This is the time whenSIRT1 activity is at its maximum and 
acetylated histone levels decline to their minimum ~5 hours later.   
 
NAD+ levels oscillate by approximately 40% during each circadian cycle, as 
shown in Figure 21, in response to oscillations in NAMPT protein levels; NAD+ 
levels oscillate in phase with NAMPT levels. Similar changes in oscillations levels 
have been seen experimentally (Nakahata, Sahar et al. 2009; Ramsey, Yoshino 
et al. 2009). This decline in the NAD+ levels is a product of several SIRT1 
deacetylation processes captured by the current model, as well as the basal 
degradation of NAD+ levels via processes external to the model.   
 
Figure 22 shows that the current model retains the phase dynamics present in 
the Hong 2009 model that are critical in the modeling of circadian systems. There 
is a lag of ~3 hours between the peak of PER mRNA and the peak in PER 
monomer levels; this is similar to experimental results seen for mammalian 
circadian rhythms (Reppert and Weaver 2001). Peaks in the PER monomer 
levels then proceed prior to the peak in the PER dimer levels several hours later, 
and peak levels in the PER dimer are then antiphase to the levels of the 
transcription factor BMAL1/CLOCK.  
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Figure 19: Current model time series. Blue/Square: CRY/PER mRNA, Green/Down 
Triangle: BMAL1/CLOCK, Red/Plus: CRY/PER, Cyan/Up Triangle: CRY/PER Dimer, 
Purple/X-Mark: NAMPT mRNA, Black/Circle: NAMPT protein. Parameters taken from 
Table 1 for the current model).  
 
 
Figure 20: Current model time series for histones and relaxed chromatin. 
Blue/Circle: NAMPT acetylated histone levels, Green/Up Triangle: CRY/PER acetylated 
histone levels, Red/Square: CRY/PER Relaxed Promoter, Cyan/Down Triangle: NAMPT 
Relaxed Promoter. Parameters are from Table 1 for the current model. 
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Figure 21: Current model time series for NAD+; Blue/Circle: NAD+ concentration. 
Simulation parameters from Table 1 for the current model.  
 
0 10 20 30 404
4.5
5
5.5
6
6.5
7
7.5
Co
nc
en
tra
tio
n 
(A
U)
Time (h)
 
 
  
104 
 
Figure 22: Comparison of current (Top) and Hong 2009 (Bottom) models. Red: 
CRY/PER mRNA, Green: BMAL1/CLOCK, Blue: CRY/PER protein, Cyan: CRY/PER 
Dimer. Only species common to both models are included. 
  
The Hong 2009 model possesses an autocatalytic positive feedback loop 
involving PER that is a necessary mechanism in order to sustain oscillations 
(Hong, Zámborszky et al. 2009). This mechanism requires that differential 
stabilities exist between PER monomer and PER in complexes, either the dimeric 
form alone or in the dimeric form complexed with BMAL1/CLOCK. This 
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mechanism arises from experimental evidence in the Drosophila circadian clock 
by Kloss et al. wherein PER complexes were shown to be less susceptible to 
degradation (Kloss, Price et al. 1998). The current model exhibits the same 
autocatalytic requirement with a smaller value for the degradation of the PER 
dimer (kcp2d) than for the degradation of the monomeric PER form (kcpd) by two 
orders of magnitude. In contrast to the Hong 2009 model, which possesses 
values for the two parameters (kcpd and kcp2d) with a smaller difference, we 
assume the activity of SIRT1 (VSIRT1c) in the destabilization of PER in either 
monomeric or in complexes to be equivalent in the current model, which means 
that kcpd2d accounts for a smaller portion of the degradation of the PER dimer in 
the current model.  
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5.3.2 Model Robustness to Parameter Variation 
 
 
Figure 23: Model robustness as indicated by alterations in maximum peak-to-peak 
amplitude and period. Red: Current model parameter values. Blue: Perturbed 
parameter values individually increased and decreased by 20%. 
 
Due to the importance of circadian rhythms in the synchronization of biological 
processes, circadian oscillations must be robust to minor perturbations and must 
stably oscillate in the presence of varied parameters resulting from individual 
variation. The results of a study of the circadian rhythms of 72 mice from 12 
inbred mouse strains showed this robustness of circadian oscillations (Schwartz 
and Zimmerman 1990). Across the combined strains, the period mean was 23.53 
(range 22.94 to 23.93) hours. We expected a similar robustness in the current 
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individually using a method that has been used in computational studies 
previously (Goldbeter 1995; Smolen, Hardin et al. 2004). 
 
Model robustness was tested by increasing and decreasing parameter values 
individually by 20% and plotting the resulting amplitudes of PER mRNA (often 
used as an experimental proxy in PER luciferase experiments) against the 
oscillation periods. The results of this testing are shown in Figure 23, and this 
testing suggests that the model is robust to parameter perturbations. Out of these 
simulations with perturbations tested none of the parameter sets resulted in 
periods that deviated from 24 hours by more than 3 hours. A majority of the 
parameter perturbations clustered near the current model parameter values from  
Table 1 (this is shown in red in Figure 23) with only slight increases or decreases 
of the period and amplitude. Stress input variables: Dex, kchk2, kchk2c, and kparp are 
set to 0 in the current model parameter set, and therefore, they are not expected 
to, nor did they, have any effect during the sensitivity testing.     
 
Three parameters resulted in periods less than 23 hours and PER mRNA 
amplitudes less than 0.4 AU. All three of these parameters affected PER, either 
mRNA or protein, levels. Decreases of 20% to PER protein synthesis rate (kcps) 
and PER mRNA synthesis rate (VM), resulted in this behavior, while an increase 
of 20% to the PER mRNA degradation (kmd) also resulted a similar behavior with 
a decreased amplitude and period. A 20% decrease in PER mRNA degradation 
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resulted in the opposite behavior with both an increase in amplitude and period; 
as shown in Figure 23, this is the only parameter that resulted in periods greater 
than 26 hours.  
 
Next, phase response curves (PRCs) were generated using pulses of 
dexamethasone (Dex) which trigger the transcription of PER to draw a 
comparison with the Hong 2009 model. Phase response curves illustrate the 
relationship between the timing of a perturbation and the effect of the 
perturbation on a circadian oscillation in the form of a phase shift (Johnson 
1999). There are two types of PRCs, Type 1 and Type 0. The resulting PRC is 
often dependent on the strength of the perturbation with Type 1 PRCs occurring 
at lower perturbations than Type 0. At low values of Dex (Dex=0.15), a Type 1 
PRC (shown in Figure 24) is produced whereby there is a continuous transition 
between phase advancements (positive values on the PRC) and delays 
(negative values) in response to the dexamethasone stimulus. At high values of 
Dex (Dex = 20), a Type 0 PRC is produced with a discontinuity existing between 
the phase advancements and delays of the system, shown in Figure 25.   
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Figure 24: Type 1 PRC.  
 
 
Figure 25: Type 0 PRC. 
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NAD+ via SIRT1 activity. Current literature contains a contradiction as to the 
effect of SIRT1 inhibition on PER2 mRNA levels. Nakahata et al. have shown 
that the inhibition of SIRT1 activity leads to an increased amplitude in the levels 
of PER2 mRNA (Nakahata, Kaluzova et al. 2008; Nakahata, Sahar et al. 2009). 
Asher et al. have shown the reverse that an inhibition SIRT1 activity results in a 
decrease in PER2 mRNA levels (Asher, Gatfield et al. 2008). Both amplitude 
increases and decreases may be theoretically possible via SIRT1 activity, since 
SIRT1 can affect both the positive and negative regulation arms of circadian 
rhythms. We first began by decreasing the rate of NAD+ biosynthesis. As shown 
in Figure 26, this result agreed with Asher et al. by qualitatively producing a 
decrease in the peak amplitude of approximately 12% in CRY/PER mRNA (M) 
levels with a decrease of 75% from the original VNADc parameter value (Asher, 
Gatfield et al. 2008).  We then further investigated this behavior by decreasing 
SIRT1 activity by reducing VSIRT1c (non-histone deacetylation activity) and 
VSIRT1d (histone deacetylation activity) to determine if either of these 
parameters would result an amplitude increase of CRY/PER mRNA (M). Similar 
to Asher et al., a decrease in VSIRT1c results in an amplitude decrease, as 
shown in Figure 27 (Asher, Gatfield et al. 2008). Similar to Nakahata et al., a 
decrease in VSIRT1d results in an amplitude increase, as shown in Figure 28 
(Nakahata, Kaluzova et al. 2008; Nakahata, Sahar et al. 2009). Figure 29 shows 
the percentage of amplitude change over the parameter values that exhibit stable 
oscillations for the SIRT1-related parameter values.  
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Figure 26: The effect of NAD+ biosynthesis decrease on CRY/PER mRNA levels. 
Red: Simulation using parameter values from Table 1. Blue: Simulation using parameter 
values from Table 1 with a 75% decrease in VNADc value.  
 
 
Figure 27: The effect of SIRT1 inhibition on non-histone components on CRY/PER 
mRNA levels. Red: Simulation using parameter values from Table 1. Blue: Simulation 
using parameter values from Table 1 with a 25% decrease in VSIRT1c value. 
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Figure 28: The effect of SIRT1 inhibition on histone components on CRY/PER 
mRNA levels. Red: Simulation using parameter values from Table 1. Blue: Simulation 
using parameter values from Table 1 with a 25% decrease in VSIRT1d value. 
 
 
Figure 29: Peak amplitude change for SIRT1-related parameter values. 
Green/Square: VNADc; Red/Circle: VSIRT1c; Blue/Triangle: VSIRT1d. Data points 
shown for region of stable oscillation. 
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allows the examination of DNA damage as simulated by the activation of CHK2 
(kchk2) to phosphorylate PER monomer and dimer that triggers their degradation, 
and the second being sharp decreases in NAD+ levels on the circadian clock 
using changes in kparp to simulate PARP1 activity. As a major participant in DNA 
damage response, PARP1 activity becomes greatly increased in response to 
DNA strand breaks and is recruited to the sites of DNA damage in a matter of 
minutes (D'Amours, Desnoyers et al. 1999). Since ionizing radiation results 
primarily in phase advancement, we asked whether perturbations in PARP1, 
singly or in combination with CHK2, could produce similar phase responses, and 
if so by what mechanism these phase advancements arise.   
 
To compare the phase responses between simulations, we use the measure 
applied by Hong et al., which is to take the ratio of the maximum phase 
advancement in a PRC to the maximum phase delay in the PRC (Hong, 
Zámborszky et al. 2009). Table 3 shows these PRC ratio results for both the 
Hong 2009 model using the current model and re-parameterized (using the 
parameters from Table 1) and for the current model under various parameter 
conditions. With the re-parameterized model, we first perturb the model using the 
same kchk2 (kchk2=0.2) from Hong et al. (There is a discrepancy in values for the 
ratio (3.54 as originally published versus 3.0193 here), but we believe these may 
be a by-product of numerical analysis and we use our value as the point of 
comparison.) Perturbing the current model using the same kchk2 (kchk2=0.2) value 
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increases the advance-delay ratio. The ratio is increased because the maximum 
delay magnitude is decreased by a larger percentage than the maximum 
advance magnitude.  
 
We next calculated the advance-delay ratio using only kparp (kparp=20) for a 
treatment duration of two hours. This yielded a ratio result similar to the one 
observed for the re-implemented Hong 2009 model, 3.0070 versus 3.0193, 
respectively. We next considered whether a combination of perturbations would 
yield higher advance-delay ratio values. Using the values kchk2=0.1 and kparp=20, 
we calculated a ratio value slightly greater than the ratio value for the CHK2 
perturbation alone in the current model, 7.6845 versus 7.5161, respectively. This 
is with a CHK2 value of half the value used for the Hong 2009 re-
parameterization. If we increase the value of kchk2 to 0.2, we produce a larger 
ratio value of 22.6498 and that has a near bimodal appearance; numerically, this 
is caused by a decrease in the magnitude of the maximum delay. Within the 
context of the model this effect has a direct relation on the activities of SIRT1, 
both as an inhibitor of transcription and as a mechanism for the destabilization of 
PER protein. This effect of this CHK2 perturbation occurs at a circadian time of 
10 hours, shown in Figure 30, which is during peak of PER dimer levels (the 
dominant form of the repressor in the system), shown in Figure 19. This 
degradation allows mRNA levels of PER and NAMPT to rise in advance of the 
unperturbed model thereby resulting in a strong phase advancement. The delays 
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for this CHK2-dependent PRC occur at troughs of PER dimer levels. This 
degradation of the PER dimer repressor at this point causes a slight increase in 
the maximum PER mRNA level relative to the unperturbed model in the 
subsequent circadian cycle resulting in the delay observed in the CHK2-
dependent PRC.  
 
The CHK2-dependent PRC is in contrast to the PARP-dependent PRC, shown in 
Figure 30, at the highest value tested (kparp=20). At this value, a Type 1 PRC is 
also produced, but whereas the CHK2 perturbation degrades PER dimer levels, 
the simulated consumption of NAD+ by PARP removes an inhibitory effect (the 
deacetylation of PER leading to its degradation by the activity of SIRT1) on this 
repressor causing an opposite effect; the peak of the PARP-dependent PRC 
occurs at roughly circadian time 20 hours and its trough at circadian time 10 
hours. This causes an inactivation of transcription by repressing the activity of 
BMAL1/CLOCK, which acts as both the transcription factor complex and as the 
histone acetylatransferase in the model. Therefore, these two perturbations, 
NAD+ depletion and PER degradation, may have different effects depending on 
the circadian time. The disparate effects of these two perturbations are seen in 
Figure 30; advance-delay ratio results are listed in Table 3. In combinations of 
the two perturbations, a bimodality in the PRC emerges at larger values of the 
two perturbations, which is not directly seen experimentally in the observations 
by Oklejewicz et al. suggesting that if this is a mechanism that exists biologically, 
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then the balance between these two forms of perturbation may be under 
additional regulation (Oklejewicz, Destici et al. 2008). Yet, the phase response 
curves seen experimentally in response to DNA damage are undoubtedly the 
products of several forms of perturbation that each may have a dominant effect 
depending on the phase of the system during perturbation. 
 
 
Figure 30: PRCs for various parameter combinations of kchk2 and kparp. 
Magenta/Plus: Advance to Delay Ratio: 45.7412; Light Blue/Diamond: Ratio: 7.6848; 
Cyan/Square: Ratio: 30.1066; Green/X-Mark: 22.6498; Black/Down Triangle: Ratio: 
3.3353; Orange/Circle: Ratio: 7.5161; Red/Up Triangle: Ratio: 3.007. Details on 
parameter values used are found in Table 3. 
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5.4 Discussion/Conclusions  
Here we have expanded on the work of both Hong et al. and Smolen et al. to 
produce a simple mathematical model that connects circadian rhythms to DNA 
damage response and metabolism via the regulation of chromatin remodeling 
(Smolen, Hardin et al. 2004; Hong, Zámborszky et al. 2009).  
This model predicts a molecular mechanism through which multiple forms of 
perturbation, as a result of DNA damage, and multiple post-translational 
modifications can reproduce an experimentally observed phase response curve 
PRC. We began with the hypothesis that the activities of SIRT1 and PARP1 in 
regulating the circadian rhythm could have an impact on the primarily phase 
advancement behavior seen in circadian oscillations during the response to 
genotoxic stress given their known interactions with core circadian clock 
components. To investigate this question, we expanded a previous model to 
account for the activity of SIRT1 in the regulation of transcription and circadian 
clock components and the activity of PARP1 during DNA damage response. The 
model reveals that the regulation of the circadian clock may be wired in a way 
that integrates multiple forms of post-translational modification as a mechanism 
to respond to environmental stress; in the case of acetylation, this post-
transcriptional modification is controlled using a circadian feedback mechanism 
through regulation of NAMPT. We examined phase response curves resulting 
from various conditions; we did this by using the simulated effects of CHK2 and 
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PARP1 activity. The results of our in silico study help to confirm the potential for 
CHK2 involvement in producing the experimentally observed PRC in the 
presence of an autocatalytic positive loop regulating PER. These findings are 
expanded to suggest that NAD+ depletion via PARP1 activity can produce a 
similar PRC result as that observed through the removal of the SIRT1 inhibitory 
effect, and moreover, raising the possibility that combinations of the two 
perturbations can also yield a similar effect. These results suggest that multiple 
perturbations may work in concert to produce the observed PRC. 
 
This model also addresses an apparent contradiction in the literature as to the 
effect of SIRT1 inhibition on the levels of PER2 mRNA (Asher, Gatfield et al. 
2008; Nakahata, Kaluzova et al. 2008; Nakahata, Sahar et al. 2009). Here we 
showed that differential SIRT1 activity targeting either specifically histone or non-
histone component deacetylation may account for this contradiction. 
Alternatively, this contradiction may suggest an additional mechanism that was 
not under experimental control between the two sets of observations and may 
also be missing from the current model presented here. A recent publication by 
Xydous et al. has suggested that the byproduct of the SIRT1 activity, 
nicotinamide, (though not specific to its reaction and not accounted for in the 
current model) may be able to affect histone methylation levels leading to 
alterations in gene expression in a manner that is independent of SIRT1 activity 
(Xydous, Sekeri-Pataryas et al. 2012). Though the inclusion of histone 
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methylation is outside the scope of the current model, this is a potential avenue 
for future examination and may further add to our understanding of how multiple 
post-translational modifications are co-regulated to affect circadian activity. 
 
One part of this system that remains to be explored through a more 
comprehensive model would include a more complete description of the 
salvaging of NAD+, including the activity of NMNAT1 that yields an intermediate 
step in this process. Although NAMPT is the rate-limiting step in the salvage 
process, it catalyzes the first step in the conversion of nicotinamide (the by-
product of SIRT1 and PARP1 catalysis) into nicotinamide mononucleotide; a 
substrate that is subsequently converted into NAD+ by NMNAT1 (Rongvaux, 
Andris et al. 2003). In the current model, only NAMPT has been included, 
because it is under circadian control, and because it is known to be rate limiting 
in the production of NAD+. Yet several publications have shown that SIRT1 can 
bind to nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), and it has 
been hypothesized that this activity may help to stimulate SIRT1 activity (Zhang, 
Berrocal et al. 2009). This would be an interesting next step to pursue, as well as 
the more detailed PARP1 dynamics that account for the negative feedback cycle 
in these dynamics due to its auto-modification capability (D'Amours, Desnoyers 
et al. 1999).  
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As the underlying mechanisms regulating the circadian clock become better 
understood with respect to the effects of post-translational modifications, such as 
acetylation, methylation, sumolyation, and ubiquitination, the addition of these 
factors can be used to refine current models of circadian rhythms.  
 
5.5 Supporting Information  
Parameter Description Current 
Model 
Hong 
2009 
Dex Rate of CRY/PER mRNA synthesis by 
dexamethasone 
0 0 
kms Rate of CRY/PER mRNA synthesis 0 1 
J Michaelis constant for BMAL1/CLOCK 
binding to CRY/PER promoter 
0 0.3 
kmd Rate of CRY/PER mRNA degradation 0.13857 0.1 
kcps Rate of CRY/PER protein synthesis 0.40453 0.5 
kcpd Rate of CRY/PER protein degradation 0.48936 0.525 
ka Rate of CRY/PER dimer association  49.9712 100 
kd Rate of CRY/PER dimer disassociation  0.36005 0.01 
kp1 Rate for monomer phosphorylation 9.4531 10 
Jp Michaelis constant of protein kinase (Casein 
Kinase 1 Epsilon, CSNK1E) 
77.9254 0.05 
kchk2 Rate of phosphorylation by CHK2 0 0 
kicd Rate of inactive complex 
(BMAL1/CLOCK/(CRY/PER)/(CRY/PER)) 
degradation  
0 0.01 
kcp2d Rate of CRY/PER dimer degradation 0.0025 0.0525 
kica Rate of inactive complex association 28.178 20 
kchk2c Rate of phosphorylation by CHK2 0 0 
kp2 Rate for dimer phosphorylation 0.36296 0.1 
Tftot Total amount of BMAL1/CLOCK 0.84792 0.5 
KTFCP Binding affinity of BMAL1/CLOCK to 
CRY/PER promoter  
0.020133 0 
KCP2CP Binding affinity of CRY/PER dimer to 
CRY/PER promoter  
0.20757 0 
KTFNP Binding affinity of BMAL1/CLOCK to NAMPT 
promoter  
0.040267 0 
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KCP2NP Binding affinity of CRY/PER dimer to 
NAMPT promoter  
0.21591 0 
kcpdeac Rate of CRY/PER promoter deacetylation 0.099 0 
knpdeac Rate of NAMPT promoter deacetylation 0.098073 0 
VM Rate of CRY/PER expression 0.40053 0 
VN Rate of NAMPT expression 0.56383 0 
N Hill coefficient for CRY/PER mRNA 
synthesis  
5.1858 2 
nac Value used to describe the steady state 
values for promoter accessibility 
1.6107 0 
Tconst_np Time constant for the relaxation of NAMPT 
promoter to steady state value 
0.26014 1 
Tconst_cp Time constant for the relaxation of CRY/PER 
promoter to steady state value 
0.22107 1 
VSIRT1c Rate of SIRT1 activity (non-histone 
deacetylation) 
0.094568 0 
knadd Rate of NAD+ degradation 1.3309 0 
knd Rate of NAMPT mRNA degradation 0.16337 0 
knps Rate of NAMPT protein synthesis 0.20238 0 
knpd Rate of NAMPT protein degradation 0.16024 0 
VNADc Rate of NAD+ production 5.2479 0 
kaCPSIRT1 Disassociation constant of SIRT1 and NAD+ 
(Used with non-histone-related equations) 
0.10491 0 
kbCPSIRT1 Michaelis constant for non-histone 
substrates  
0.098395 0 
kparp Rate of PARP1 activity 0 0 
VSIRT1d Rate of SIRT1 activity (histone 
deacetylation) 
0.070926 0 
 
Table 1: Parameter values for current and Hong 2009 model
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Species Description Current 
Model 
Hong 2009 
Model 
M CRY/PER mRNA 1.4 1.4 
TF BMAL1/CLOCK complex 0.13 0.13 
CP CRY/PER protein 0.037 0.037 
CP2 CRY/PER dimer  0.046 0.046 
N NAMPT mRNA 1.5 1.5 
NP NAMPT protein 1 1 
ACNP Single histone acetylation (NAMPT 
promoter)  
0 0.01 
ACCP Single histone acetylation (CRY/PER 
promoter)  
0 0.01 
OPCP DNA Accessibility Value (CRY/PER 
promoter) 
0 0 
OPNP DNA Accessibility Value (NAMPT 
promoter) 
0 0 
NAD NAD+ 3 3 
 
Table 2: Initial values for the current and the Hong 2009 model. 
 
Model kchk2 Value kparp Value Maximum 
Delay (h) 
Maximum 
Advance 
(h) 
Advance to 
Delay Ratio 
Hong 2009 0.2 0 -1.6766 5.0623 3.0193 
Base Model 0.2 0 -0.4922 3.6996 7.5161 
Base Model 0 10 -0.9123 3.0428 3.3353 
Base Model 0 20 -1.6618 4.9971 3.0070 
Base Model 0.1 10 -0.0612 2.7985 45.7412 
Base Model 0.1 20 -0.6026 4.6307 7.6845 
Base Model 0.2 10 -0.0848 2.5542 30.1066 
Base Model 0.2 20 -0.1883 4.2642 22.6498 
 
Table 3: Results for the analysis of phase shifting behavior by variable kparp. 
 
MIM 
Annotation 
Description Equation 
A1 CP mRNA synthesis (OPCP) 1 
A2 CP mRNA degradation 1 
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A3 CP mRNA synthesis (Dex induction) 1 
A4 CP mRNA synthesis (TF) 1 
A5 IC association 2 
A6 IC degradation (phosphorylation) 2 
A7 IC degradation (CHK2) 2 
A8 IC degradation 2 
A9 IC disassociation 2 
A10 IC degradation (NAD) 2 
A11 CP degradation (NAD) 3 
A12 CP degradation (CHK2) 3 
A13 CP degradation (phosphorylation) 3 
A14 CP degradation  3 
A15 CP synthesis  3 
A16 CP2 degradation (NAD) 4 
A17 IC association 4 
A18 CP2 degradation (CHK2) 4 
A19 CP2 degradation (phosphorylation) 4 
A20 IC degradation 4 
A21 IC disassociation 4 
A22 CP2 disassociation 4 
A23 CP dimerization 4 
A24 N mRNA synthesis (OPNP) 5 
A25 N degradation 5 
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A26 NP degradation 6 
A27 NP synthesis 6 
A28 NP acetylated histone deacetylation (NAD) 7 
A29 ACNP histone acetylation 7 
A30 NP acetylated histone deacetylation 7 
A31 CP acetylated histone deacetylation (NAD) 8 
A32 ACCP histone acetylation 8 
A33 CP acetylated histone deacetylation  8 
A34 OPCP synthesis 9 
A35 OPNP synthesis 10 
A36 CP acetylated histone deacetylation (NAD) 11 
A37 NP acetylated histone deacetylation (NAD) 11 
A38 IC degradation (NAD) 11 
A39 CP2 degradation (NAD) 11 
A40 CP degradation (NAD) 11 
A41 NAD degradation 11 
A42 NAD synthesis 11 
A43 NAD degradation (PARP1) 11 
A44 CP2 disassociation 3 
A45 CP dimerization 3 
 
Table 4: Description of MIM wiring diagram and connection to model equations. 
The description column contains species labels from Table 2; IC refers to the “inactive 
complex” from Equation 14. 
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6 DISCUSSION AND CONCLUSIONS 
6.1 Molecular Interaction Maps 
Computational biology has seen rapid change in recent decades. Large-scale 
sequencing and gene expression studies continue to push experimental 
boundaries in biology leading to an explosion of data (Schmidt 2003). This leads 
to the problem known generally as a “big data” problem in biology where our 
ability to store and analyze information is continually challenged Often lost in 
discussions about big data in the context of single experiments generating large 
volumes of information are big data challenges that arise from the variety of data 
rather than volume. To maximize the benefits of integration, data need to be 
woven across a range of structured pathway and genomic databases alongside 
unstructured data from scientific publications and clinical reports into a single 
tapestry with a common language to allow a wide-range of biologists to “ask” 
questions of this data.  
  
Addressed here is one approach to this challenge based on using the Molecular 
Interaction Map (MIM) notation as the basis. A suite of software tools was 
developed around the MIM notation, which allows users to manually curate 
information from a large number of resources. Usage of this software allows the 
simplified creation of valid, well-annotated, machine-readable diagrams with links 
to external data repositories suitable as illustrations of signaling pathways in 
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publications and which can serve as a starting point for deeper analysis of 
pathways. This can be achieved through the use of plugins like the Faceted 
Search plugin that allows users to bridge MIM representations with local 
experimental results and data provided by remote web services. For software 
developers, this work simplifies the incorporation of the MIM notation into 
additional software tools and provides programmatic access for the extraction of 
data from the MIM diagrams for their analysis and integration with other projects. 
This work has already yielded a second diagram editor for the MIM notation 
called MIMTool (http://code.google.com/p/mimtool/). While MIMTool provides 
fewer features than the combined set found in the PathVisio-related tools 
presented here, it is an encouraging sign. 
 
While the software developments presented here do provide many key 
components for the usage of the MIM notation, there are limitations to this work 
that will need to be further addressed. Future work related to the notation will 
focus on the expansion of the notation to additional biological concepts as use 
cases present themselves. The software development for the MIM notation will 
also continue towards of the goal of simplifying the creation and analysis of MIM 
diagrams by human users, the expanded use of the notation through its 
incorporation into databases, such as WikiPathways, and the auto-generation of 
MIM diagrams from suitable databases, such as Pathway Commons (Pico, 
Kelder et al. 2008; Cerami, Gross et al. 2011).  
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One remaining challenge outside of the scope of the current work is in the 
analysis of MIM diagrams due to the nature of MIM diagrams as networks. The 
MIM notation seeks to represent the complex biological systems and to do so 
has extended beyond the idea of a basic network graph in which two nodes are 
connected by a single edge. Biological systems are not so simple and biological 
processes are often characterized by more than two interacting species. It may 
become necessary to analyze MIM diagrams in a manner that overcomes this 
conceptual limitation. Hypergraphs have been suggested, but whether MIM 
diagrams can be characterized as hypergraphs and how basic network graph 
analysis techniques may translate to hypergraphs and MIM diagrams remains an 
open question (Klamt, Haus et al. 2009).  
 
Another major remaining challenge is in the auto-generation of MIM diagrams. 
The key underpinning to this work will be in the development of suitable layout 
algorithms that can handle large networks, provide aesthetic results, and make 
use of biological context during rendering. The development of these algorithms 
has been outside the scope of presented work, yet they are important in the 
adoption of the MIM notation as they simplify the work of the end user in creating 
and editing the diagrams. 
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In terms of a wider systems biology community, this work not only provides tools 
for the creation and usage of MIM diagrams, but facilitates the development of 
better training materials for potential users in outreach efforts. Validation support 
as part of this software suite gives novice users faster feedback in learning the 
capabilities of the notation. With respect to related efforts, this project provides 
the larger community with building blocks in terms of ideas and software. Already 
a validation framework similar to one presented here for MIM has been 
developed for the Systems Biology Graphical Notation (SBGN); such exchanges 
between related projects aid in the unification of efforts (van Iersel, Villeger et al. 
2012). 
 
6.2 Modeling SIRT1 and PARP1 
From a starting point of two proteins, SIRT1 and PARP1, and a focus on DNA 
damage response a large network has been constructed connecting several key 
biological processes, including metabolism, chromatin remodeling, and circadian 
rhythms with DNA damage response. The SIRT1 and PARP1 network focuses 
on the regulation and interplay between the two proteins, including: 1) the post-
transcriptional regulation of SIRT1 and PARP1, 2) the co-regulatory mechanisms 
existing between these two proteins, and 3) common regulatory targets of the 
two proteins. Undoubtedly, this network could continue to be expanded with 
currently known information about proteins present at the periphery of this 
network as well as additional information about the two proteins as it is 
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discovered. Herein lies the utility of producing machine-readable representations 
of this knowledge utilizing tools developed for the MIM notation that allow this 
data to be expanded more easily as the information becomes available and 
computationally utilized. 
 
Networks such as these highlight the scope of our current knowledge and help us 
see what remains to be uncovered. In its current form, this network highlights the 
interactions known to exist between SIRT1, PARP1 and core circadian 
components and also highlights the deficit in our understanding of potential 
mechanisms that link this DNA damage response and circadian rhythms via 
SIRT1 and PARP1. The interactions from the SIRT1 and PARP1 network were 
taken as a starting point for the development of an in silico model looking at the 
dynamics of these two proteins that may potentially be involved in the regulation 
of the circadian clock resetting behavior in response to DNA damage. The model 
makes use of several key experimental observations, including the circadian 
regulation of NAMPT and its role in NAD+ synthesis, the histone acetylation 
activity of CLOCK and histone deacetylation activity of SIRT1, the destabilization 
of PER2 caused by SIRT1 deacetylation, and the competition for NAD+ supplies 
by SIRT1 and PARP1. 
 
As expected, the developed model simulates many of the behaviors of the 
molecular circadian clock, including simulating a circadian oscillation with a 
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period of 23.8 hours and simulating key phase relationships known to exist 
between core circadian clock components that permit oscillation of the system. 
These circadian oscillations are robust to perturbations of all model parameters 
yielding period fluctuations of no more than three hours. This model was used to 
then develop mechanistic predictions showing the potential for cooperation of two 
post-translational modifications (phosphorylation and acetylation) to produce a 
characteristic phase advancement behavior seen in circadian oscillations in 
response to genotoxic stress. Previously, it had been hypothesized that 
degradation triggered by phosphorylation could play a role in this behavior. The 
current work extends this by predicting that utilization of NAD+ by PARP1 during 
DNA damage response may produce a complementary effect through the 
inhibition of SIRT1 by PARP1 via the reduction of NAD+ levels.   
 
Despite the novel predictions made by this work, the model does have limitations 
and could be further extended in future work. First, this model suffers from a key 
limitation similar to other models of biological systems through its use of arbitrary 
concentration values due to the incomplete quantitative data being known about 
modeled systems. Second, common to the modeling of any biological system, it 
falls on the intuition of the modeler to determine the boundaries of the system. In 
this case intuition was drawn through careful review through the use of the MIM 
diagrams, yet additional interactions may play key roles in the modeled 
behaviors. The model could be further extended with a greater level of detail in 
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the production and utilization of NAD+. One protein that could be included is 
nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) that is known to 
be involved in the production of NAD+ and the efficient use of NAD+ by SIRT1. In 
terms of PARP1, additional interactions could also be included to describe the 
interactions between PARP1 and the circadian transcription regulation and 
greater detail in the use of NAD+ by PARP1. Beyond additional interactions that 
could be represented in the model, a future direction for this project is in the 
experimental validation of the predictions derived through the use of this model 
that would aid in the refinement of this work. 
 
6.3 Concluding Statement 
The work presented here seeks the structuring of knowledge of biological 
pathways in order to integrate this knowledge and advance our understanding of 
biological systems for the purpose of enhancing health and reducing illness. It is 
a monumental challenge that stands before us. We must approach this challenge 
with enthusiasm, but at the same time humility with regards to intellectual gains 
made. For as much as we believe that we know, we know nothing. 
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APPENDIX A FORMAL MIM NOTATION SPECIFICATION 
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APPENDIX B SIRT1/PARP1 MIM ANNOTATIONS 
Label Annotation 
A1 
PARP1 has three domains: a DNA binding domain (DBD), an auto-
modification domain, and a catalytic domain, ordered from the N to the C 
terminus (Mendoza-Alvarez H et al., 1993). 
A2 
The main function of PARP1 is the formation of ADP-ribose polymers on 
itself and other proteins, including histones where it possibly interferes with 
other histone modifications, proteins involved in protein DNA synthesis and 
repair (e.g. p53), and proteins involved in cell cycle regulation; in the case of 
the histones and p53, ADP-ribosylation has been suggested to inhibit the 
DNA binding capability of these proteins (D'Amours D et al., 1999; Hassa 
PO et al., 2006; 20525793 et al., 2010) 
A3 
The main protein that degrades PAR polymer is poly (ADP-ribose) 
glycohydrolase (PARG) (Kim MY et al., 2005). The enzymatic activity of 
PARG cleaves PAR into mono and oligo-ADP-ribose (Hassa PO et al., 
2006). 
A4 
Phosphorylation at S47 by mTOR causes the inhibition of SIRT1 (Back JH 
et al., 2011). 
A5 
Phosphorylation at S47 by mTOR causes the inhibition of SIRT1 (Back JH 
et al., 2011). 
A6 
Cyclin B/Cdk1, a cell cycle-dependent kinase, is capable of phosphorylating 
SIRT1 at T530 and S540. Phosphorylation at these two sites decreases the 
activity of SIRT1 and disrupts progress of the cell cycle (Sasaki T et al., 
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2008) 
A7 
DYRK1A and DYRK3 phosphorylate SIRT1 at T522 stimulating the 
deacetylation of p53 by SIRT1 (Guo X et al., 2010). 
A8 
AMPK phosphorylates SIRT1 at T344 inhibiting its the ability to decacetylate 
p53, a known target of SIRT1 (Lee CW et al., 2012). 
A9 
Methylation of SIRT1 by Set7/9 at K233, K235, K236, and K238 inhibits the 
SIRT1-mediated deacetylation of p53 (Liu X et al., 2011). 
A10 
Sumolyation at K734 by SUMO1 increases the activity of SIRT1; 
association with SENP1, a nuclear desumoylase, reduces the activity of 
SIRT1 in response to genotoxic stress (Yang Y et al., 2007). 
A11 
Transnitrosylation of SIRT1 by GAPDH at C387 and C390 has been 
suggested to inhibit the activity of SIRT1 (Kornberg MD et al., 2010). 
A12 
DNA-PK phosphorylates PARP1 though its effect on PARP1 DNA binding 
or catalytic activity is unknown (Ruscetti T et al., 1998). 
A13 
Phosphorylation of PARP1 by AMPK and ERK1/2 has been shown to 
enhance its auto-modification activity (Kauppinen TM et al., 2006; Walker 
JW et al., 2006). 
A14 
PARP1 is acetylated by p300/CBP; this acetylation is involved in the 
activation of NF-kB by PARP1 (Hassa PO et al., 2005). 
A15 
PARP1 is also sumolyated both in vivo and in vitro by SUMO1 and SUMO3 
at K486 of PARP1's auto-modification domain. This sumolyation does not 
affect the ADP-ribosylation activity of PARP1, but inhibits the ability of p300 
to acetylate PARP1; this modification also inhibits the expression of genes 
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that are transcriptionally targeted by PARP1 (Messner S et al., 2009). 
A16 
Increased levels of PARP1 acetylation occur in response to mechanical 
stress (Rajamohan SB et al., 2009). 
A17 
The rate-limiting protein in the conversion of NAM back to NAD+ is 
nicotinamide phosphoribosyltransferase (NAMPT), which catalyzes the 
reaction of nicotinamide into nicotinamide mononucleotide (NMN). (Revollo 
JR et al., 2004). 
A18 Protein kinase C phosphorylates NMNAT1 at S136 (Berger F et al., 2007). 
A19 
A similar interaction has been shown to occur with SIRT1, whereby SIRT1 
binds to NMNAT1 (Zhang T et al., 2009). 
A20 
SIRT1 can act as a histone deacetylase, and it has been shown to 
deacetylase H1K26, H3K9, H3K14, and H4K16 (Imai S et al., 2000; 
Vaquero A et al., 2004). 
A21 
PARP1 can modify histones H1, H2AK13, H2BK30, H3K27, H3K37, and 
H4K16 to possibly regulate transcription (Krishnakumar R et al., 2010; 
20525793 et al., 2010). 
A22 
Acetylation at H4K16 inhibits the ADP-ribosylation of histone H4 (20525793 
et al., 2010). 
A23 
PARP1 is activated by either single strand breaks or double strand breaks 
(D'Amours D et al., 1999). 
A24 
Once activated PARP1 may act to prevent additional damage to the DNA in 
the conversion of single-strand breaks (SSB) to double-stranded breaks 
(DSB) through its (ADP-ribosyl)ation activity (Woodhouse BC et al., 2008). 
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A25 
PARP1 is involved in DNA repair through its associations with base excision 
repair (BER) enzymes such as polymerase beta, XRCC1 and DNA ligase III 
(de Murcia JM et al., 1997). 
A26 
MRN is important in the response to double strand DNA breaks. It promotes 
the activation of ATM when it is bound to NBS1 via a site on the C-terminus 
of NBS1, and furthermore, it helps retain ATM at regions of DNA damage 
(Uziel T et al., 2003; Dupré 
 A et al., 2006). 
A27 
MRN is important in the response to double strand DNA breaks. It promotes 
the activation of ATM when it is bound to NBS1 via a site on the C-terminus 
of NBS1, and furthermore, it helps retain ATM at regions of DNA damage 
(Uziel T et al., 2003; Dupré 
 A et al., 2006). 
A28 
Typically, ATM exists as an inactive dimer; autophosphorylation at S1981 
leads to its monomerization and activation during DNA damage (Yuan Z et 
al., 2007). 
A29 
It has been shown that PARP1 binds to ATM, an interaction that is 
stimulated by DNA damage, and that the automodification of PARP1 leads 
to ATM activation (Aguilar-Quesada R et al., 2007). 
A30 
NBS1 is phosphorylated at S343 by ATM, which is important to the DNA 
damage response (Yuan Z et al., 2007). 
A31 
In order for NBS1 to be phosphorylated, it is necessary for NBS1 to be in a 
hypoacetylated state, which SIRT1 helps to maintain by deacetylating NBS1 
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both in vitro and in vivo (Yuan Z et al., 2007). 
A32 
When activated by oxidative stress, CHK2 phosphorylates HuR at several 
sites causing it to dissociate from SIRT1 mRNA, thereby reducing the half-
life of the SIRT1 mRNA (Abdelmohsen K et al., 2007). 
A33 
E2F1 induces the transcription of SIRT1, but conversely, E2F1 has been 
suggested to be a target for SIRT1 deacetylation (16892051 et al., ). 
A34 
E2F1 induces the transcription of SIRT1, but conversely, E2F1 has been 
suggested to be a target for SIRT1 deacetylation (16892051 et al., ). 
A35 
Acetylation of E2F1 stimulates the protein's DNA binding and 
transactivation activities. E2F1 is acetylated by the PCAF during DNA 
damage that helps to stabilize the protein making it more available to trigger 
an apoptotic response (Ianari A et al., 2004). 
A36 
c-Myc over-expression leads to an increase in SIRT1 expression by binding 
to the SIRT1 promoter, and over-expression of SIRT1 decreased the protein 
levels of c-Myc through deacetylation, which destabilizes c-Myc (Yuan J et 
al., 2009). 
A37 
c-MYC is capable of inducing the transcription of NAMPT and helps 
sequester DBC1, an inhibitor of SIRT1 (Menssen A et al., 2012). 
A38 
PARP1 binds to E2F1 stimulating E2F1-dependent transcription of c-MYC 
(Simbulan-Rosenthal CM et al., 2003). 
A39 
SIRT1 is able to deacetylate the RelA/p65 subunit of NF-kB at K310 to 
inhibit NF-kB transactivation activity (Yeung F et al., 2004). 
A40 PARP1 has been shown to be a direct activator of NF-[K]B through its direct 
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binding to NF-[K]B; neither the DNA binding or enzymatic activity of PARP1 
were necessary for this activation though acetylation of PARP1 by 
p300/CBP is required (Hassa PO et al., 2001; Hassa PO et al., 2005). 
A41 
p53, a well-studied tumor suppressor that acts as a transcription factor 
capable of inducing apoptosis (Levine AJ et al., 2009). 
A42 
SIRT1 has the capability of deacetylating p53 at several sites and SIRT1-
deficient cells possess hyperacetylated p53 (Luo J et al., 2001; Cheng HL et 
al., 2003; Brooks CL et al., 2009). 
A43 
p53 can repress SIRT1 expression during nutrient abundance via p53-
binding sites on the SIRT1 promoter (Nemoto S et al., 2004; Shang L et al., 
2009). 
A44 
During nutrient deprivation, FOXO3A binds to p53 leading to the loss of the 
p53-repression of the SIRT1 promoter (Nemoto S et al., 2004). 
A45 
HIC1 inhibits the expression of SIRT1 by binding to the SIRT1 promoter 
(Chen WY et al., 2005). 
A46 
In this loop, p53 stimulates the expression of miRNA-34, which 
subsequently drives down the expression of SIRT1. The consequence of 
this being that SIRT1 is less available to deacetylate p53 and inhibit p53 
activity (Yamakuchi M et al., 2009). 
A47 
Over 15 micro-RNAs have been shown to affect the expression of SIRT1 
either directly or by decreasing the expression of HuR, which stabilizes 
SIRT1 mRNA by binding on to the 3'-UTR region (Yamakuchi M et al., 
2012). 
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A48 
In humans, deleted in breast cancer 1 (DBC1) acts as an inhibitor of SIRT1 
(Zhao W et al., 2008). 
A49 
During genotoxic stress, DBC1 is phosphorylated by ATM at T454 allowing 
for the greater inhibition of SIRT1 (Yuan J et al., 2012). 
A50 
Active Regulator of SIRT1 (AROS) has been shown to bind to SIRT1 and 
help enhance the deacetylation of p53 by SIRT1 (Kim EJ et al., 2007). 
A51 
Ku70 can be deacetylated by SIRT1 at K539 and K542 and acetylation of 
Ku70 leads to the dissociation of the Ku70 and Bax (Cohen HY et al., 2004). 
A52 
The association of Ku70 and Bax sequesters Bax, thereby inhibiting 
apoptosis (Cohen HY et al., 2004). 
A53 
NBS1 helps control the interaction between Ku70 and Bax by stimulating 
the acetylation of Ku70; overall, this activity by NBS1 helps to promote 
apoptosis (Iijima K et al., 2008). 
A54 
During normal apoptosis, PARP1 is cleaved by caspases; the role of these 
cleaved fragments play is not fully understood. One possibility is that the 
resulting N-terminal fragment continues to be able to bind to DNA, which 
inhibits the activity of uncleaved PARP1 (D'Amours D et al., 2001). 
A55 
Additionally, the cleavage of PARP1 into fragments helps to prevent cellular 
energy depletion (NAD+ and ATP) in response to severe DNA damage, 
which would trigger necrosis and block repair proteins from reaching the 
damaged DNA (Koh DW et al., 2005). 
A56 
PARP1 has also been implicated in a caspase-independent apoptotic 
pathway, whereby the activation of PARP1 leads to the release of 
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apoptosis-inducing factor (AIF) from the mitochondria; AIF induces the 
fragmentation of chromatin in the nucleus to trigger apoptosis (Yu SW et al., 
2002). 
A57 
In this feedback loop, CLOCK and BMAL1 associate and form a 
heterodimeric transcription factor complex capable of binding to E-box 
promoter sites (Reppert SM et al., 2001). 
A58 
There are a large number of proteins that are regulated by the 
CLOCK/BMAL1 transcription factor complex, including the PER and CRY 
genes. Studies conducted in mice exhibit that about 10% of genes are 
controlled in a circadian manner depending on tissue type and experimental 
conditions (Ptitsyn AA et al., 2011; Reppert SM et al., 2001). 
A59 
In the nucleus, CRY proteins associate with the CLOCK/BMAL1 complex to 
inhibit transcription (Reppert SM et al., 2001). 
A60 
It has been shown that acetylation of BMAL1 at K537 helps stabilize the 
interaction between CRY and BMAL1 and that SIRT1 is capable of 
deacetylating BMAL1 at K537 (Hirayama J et al., 2007; Nakahata Y et al., 
2008). 
A61 
CLOCK is capable of acetylating the same locations as SIRT1 deacetylates: 
H3K9 and H3K14 (Imai S et al., 2000; Nakahata Y et al., 2008). 
A62 
In addition to being able to regulate the circadian clock via the deacetylation 
of BMAL1 and histones, there is also evidence of SIRT1 deacetylates PER2 
which destabilizing the protein (Asher G et al., 2008). 
A63 PARP1 is capable of ADP-ribosylating the CLOCK in a circadian manner 
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causing disruption in the association between the BMAL1/CLOCK 
heterodimer and its target genes (Asher G et al., 2010). 
A64 
SIRT6, another of the nuclear sirtuins, has been shown to have role in 
promoting DNA damage repair by binding and activating PARP1 by mono-
ADP-ribosylating PARP1, thereby triggering its auto-ADP-ribosylation 
activity (Mao Z et al., 2011). 
A65 
AMPK raises NAD+ levels that then lead to greater activity of SIRT1 (Park 
SJ et al., 2012). 
A66 
Both SIRT1 and PARP1 share the common product of NAM, and this 
product can inhibit both SIRT1 and PARP1 (Xydous M et al., 2012). 
A67 
FK866 is an inhibitor of NAMPT that has undergone Phase I clinical trials for 
cancer (Holen K et al., 2008). 
A68 
Sirtinol exhibit inhibitory effects for both SIRT1 and SIRT2 (Peck B et al., 
2010). 
A69 
PARP1 activity can be inhibited by various substances, including thymidine 
(Preiss J et al., 1971). 
A70 
NAM is converted to nicotinamide mononucleotide (NMN) by nicotinamide 
phosphoribosyltransferase (NAMPT, EC 2.4.2.12) (Sasaki Y et al., 2009). 
A71 
Nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1) 
utilizes NMN and ATP to produce NAD+ and pyrophosphate (PPi) (Sasaki Y 
et al., 2009). 
A72 
A study by Matsuoka et al. found an extensive network of proteins 
phosphorylated by ATM or ATR in response to DNA damage through a high 
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throughput screen. Of these proteins, PARP1 was shown to be one of these 
proteins (Matsuoka S et al., 2007). 
A73 
Depletion of NAD+ depletes energy stores by two methods. First, synthesis 
of NAD+ requires the use ATP by Na/NMNATs in both the de novo and 
salvage pathways (Hassa PO et al., 2006). 
A74 A likely candidate for the acetylation of NBS1 is PCAF (Yuan Z et al., 2007). 
A75 
The phosphorylation of NBS1 helps stimulate the activity of ATM through 
the MRN complex (Lee JH et al., 2007). 
A76 ATM phosphorylates CHK2 at T68 to activate it (Rogoff HA et al., 2004). 
A77 
Acetylation of E2F1 stimulates the protein's DNA binding and 
transactivation activities. E2F1 is acetylated by the PCAF during DNA 
damage that helps to stabilize the protein making it more available to trigger 
an apoptotic response (Ianari A et al., 2004). 
A78 
SIRT1 and PARP1 are enzymes that affect key post-translational 
modifications: acetylation and ADP-ribosylation, respectively, for a diverse 
group of proteins, and they are inextricably bound due to their usage of a 
common substrate, nicotinamide adenine dinucleotide (NAD+) and release 
of nicotinamide as a product (D'Amours D et al., 1999; Blander G et al., 
2004). 
A79 
The PER and CRY proteins form a heterodimeric complex that translocates 
into the nucleus and inhibits CLOCK/BMAL1 transcription activity (Reppert 
SM et al., 2001). 
A80 NAMPT is controlled in a circadian manner and SIRT1 is involved in its 
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transcriptional regulation (Nakahata Y et al., 2009). 
A81 
In the presence of elevated cAMP levels, Epac1 becomes activated leading 
to increased intracellular levels of Ca++ that activates CAMKBB, which then 
activates AMPK (Park SJ et al., 2012). 
A82 SIRT1 gene is transcribed to SIRT1 mRNA 
A83 SIRT1 mRNA is translated to SIRT1 protein. 
A84 Light induces the expression of PER (Reppert SM et al., 2001) 
A85 
Resveratrol inhibits the activity of phosphodiesterases, such as PDE4, that 
degrade cAMP (Park SJ et al., 2012). 
A86 Genotoxic stress (i.e. DNA damage) generates single strand DNA breaks 
A87 
NAD+ is a required substrate for SIRT1 and PARP1 activity (Rajamohan SB 
et al., 2009). 
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